{"gene":"MERTK","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2000,"finding":"Mutation/deletion of the Mertk gene (disrupting the splice acceptor site upstream of the second coding exon) in RCS rats causes failure of retinal pigment epithelial (RPE) cells to phagocytose shed photoreceptor outer segments, establishing MERTK as a receptor tyrosine kinase essential for this specialized phagocytic process.","method":"Positional cloning, genomic deletion mapping, transcript analysis, genetic concordance in RCS rat retinal dystrophy model","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — positional cloning with functional concordance, replicated across multiple subsequent studies confirming the same mechanism","pmids":["10699188"],"is_preprint":false},{"year":1994,"finding":"MERTK (c-mer) encodes a novel 984-amino acid transmembrane receptor tyrosine kinase with extracellular immunoglobulin and fibronectin type III domains and the kinase signature KWIAIES, classified in the Axl family; it is expressed in peripheral blood monocytes and certain neoplastic lymphocyte lines but not in normal B- and T-lymphocytes. An alternatively spliced transcript encoding a truncated, potentially soluble receptor was also identified.","method":"Anti-phosphotyrosine antibody screening of cDNA expression library, sequence analysis, Northern blot RNA expression analysis","journal":"Cell growth & differentiation","confidence":"High","confidence_rationale":"Tier 1 / Strong — original molecular cloning with domain characterization; foundational discovery replicated widely","pmids":["8086340"],"is_preprint":false},{"year":2004,"finding":"MerTK activates phospholipase C gamma2 (PLCγ2) during macrophage phagocytosis of apoptotic thymocytes: exposure to apoptotic cells induces tyrosine phosphorylation of MerTK, association of PLCγ2 with MerTK, and phosphorylation of PLCγ2; PI-PLC inhibition blocks phagocytosis without impairing adhesion.","method":"Western blotting, immunoprecipitation (Co-IP), antibody cross-linking, pharmacological inhibition of PI-PLC (Et-18-OCH3, U73122) in peritoneal macrophages and J774 cells","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus functional inhibitor assays, two cell systems, single lab","pmids":["14704368"],"is_preprint":false},{"year":2004,"finding":"Mer (MERTK) is the predominant Gas6 receptor expressed in mouse and human platelets (Axl and Rse not detected); Mer-deficient mice show decreased platelet aggregation in response to collagen, U46619, and PAR4 agonist, and are protected from collagen/epinephrine-induced pulmonary thromboembolism and ferric chloride-induced thrombosis in vivo, establishing a role for MERTK in platelet function and thrombosis.","method":"RT-PCR, Western blot, targeted gene disruption (Mer knockout mice), in vitro platelet aggregation assays, in vivo thrombosis models","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout with multiple in vitro and in vivo phenotypic readouts, single lab","pmids":["15130911"],"is_preprint":false},{"year":2008,"finding":"MerTK on dendritic cells (DCs) mediates apoptotic cell (AC)-induced inhibition of DC activation/maturation in a Gas6-dependent manner; DCs lacking MerTK kinase activity (NOD.MerTK(KD/KD)) are resistant to AC-induced suppression of proinflammatory cytokines and costimulatory molecule up-regulation, and mice lacking MerTK kinase activity show exacerbated autoimmune diabetes with increased activated pancreatic DCs.","method":"Kinase-dead knock-in mice, DC-T cell co-culture, cytokine secretion assays, adoptive transfer, streptozotocin-induced beta cell apoptosis model","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — kinase-dead knock-in with multiple functional readouts (cytokine, costimulatory molecule, diabetes model), single lab with multiple orthogonal methods","pmids":["18195070"],"is_preprint":false},{"year":2010,"finding":"Tubby and Tulp1 are novel MerTK ligands that act as bridging molecules for phagocytosis: tubby binds only MerTK while Tulp1 binds Tyro3, Axl, and MerTK; both ligands induce MerTK receptor phosphorylation and downstream signaling including non-muscle myosin II redistribution and co-localization with phagosomes; excess soluble MerTK extracellular domain blocks tubby/Tulp1-mediated phagocytosis; five minimal phagocytic determinants (K/R(X)(1-2)KKK) in Tulp1 N-terminus were defined as essential MerTK-binding motifs.","method":"Co-immunoprecipitation, receptor phosphorylation assays, blocking with soluble MerTK extracellular domain, phagocytosis assays, domain mapping by mutagenesis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — receptor binding confirmed by Co-IP with domain mutagenesis and functional phagocytosis blocking, single lab with multiple orthogonal methods","pmids":["20978472"],"is_preprint":false},{"year":2012,"finding":"MERTK overexpression in glioblastoma multiforme is associated with invasiveness; MERTK depletion disrupts rounded glioma cell morphology, decreases invasive capacity, and reduces expression and phosphorylation of myosin light chain 2, implicating actomyosin contractility as a downstream effector; MERTK also protects cells from DNA-damage-induced apoptosis in a kinase-activity-dependent manner.","method":"shRNA knockdown, overexpression of inactive MERTK mutant, invasion assays, Western blotting for myosin light chain 2 phosphorylation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and dominant-negative approaches with specific molecular readout (MLC2 phosphorylation), single lab","pmids":["22469987"],"is_preprint":false},{"year":2013,"finding":"In melanoma cells, GAS6 stimulation of MERTK activates MAPK/ERK, PI3K/AKT, and JAK/STAT downstream signaling pathways; shRNA-mediated MERTK inhibition reduces colony formation by up to 59% and diminishes tumor volume by 60% in xenograft models.","method":"GAS6 stimulation, Western blotting for downstream pathway phosphorylation, shRNA knockdown, soft agar colony formation, murine xenograft models","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ligand stimulation with downstream signaling readouts plus loss-of-function in vitro and in vivo, single lab with multiple orthogonal methods","pmids":["23585477"],"is_preprint":false},{"year":2013,"finding":"In AML cells, Gas6-stimulated MERTK activates prosurvival and proliferative signaling including phosphorylation of ERK1/2, p38, MSK1, CREB, ATF1, AKT, and STAT6; shRNA knockdown of MERTK increases myeloblast apoptosis 2-3-fold and decreases colony formation by 67-87%; MERTK knockdown prolongs survival in NOD-SCID-gamma xenograft mice.","method":"Gas6 ligand stimulation, Western blotting for signaling intermediates, shRNA knockdown, apoptosis assays, colony formation, murine xenograft model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ligand-stimulated signaling plus genetic loss-of-function in vitro and in vivo, single lab with multiple methods","pmids":["23474756"],"is_preprint":false},{"year":2013,"finding":"In melanoma, shRNA-mediated MERTK knockdown reduces colony formation and cell migration in a CDC42-dependent manner and decreases cell survival in an AKT-dependent manner; a novel kinase-domain mutation MERTK(P802S) increases cell motility relative to wild-type MERTK.","method":"shRNA knockdown, colony formation assay, migration assay, small GTPase dependency experiments, site-directed mutagenesis","journal":"Pigment cell & melanoma research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown and mutant overexpression with specific pathway readouts, single lab","pmids":["23617806"],"is_preprint":false},{"year":2014,"finding":"MERTK overexpression in MCF10A epithelial cells stimulates efferocytosis in a gain-of-function capacity that is highly dependent on apoptotic cells (phosphatidylserine interface), also stimulates AKT-mediated chemoresistance, and promotes PD-L1 expression through apoptotic cell engagement; knockdown of MERTK in MDA-MB-231 breast cancer cells reduces efferocytosis.","method":"Stable MERTK overexpression, shRNA knockdown, efferocytosis assays, AKT pathway assays, PD-L1 expression analysis, soluble TAM receptor blocking","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function in multiple cell lines with functional efferocytosis readouts, single lab","pmids":["25074939"],"is_preprint":false},{"year":2014,"finding":"MERTK undergoes proteolytic cleavage to release a soluble sMerTK form from RPE cells; sMerTK acts as a decoy receptor blocking MerTK ligands and thereby limiting phagocytic outer segment binding; blocking MERTK cleavage increases POS binding; MFG-E8 (integrin ligand) markedly increases both phagocytosis and sMerTK shedding.","method":"Conditioned media analysis, RPE-J cell phagocytosis assays, metalloprotease inhibitors, MERTK cleavage blocking reagents, interphotoreceptor matrix analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional shedding assays with receptor blocking and in vivo retinal verification, single lab","pmids":["25538233"],"is_preprint":false},{"year":2015,"finding":"Mer receptor mediates both tethering and phagocytosis of apoptotic cells by macrophages; Mer-mediated tethering and subsequent AC engulfment can be distinguished by their differential requirement for Mer kinase activity (tethering is kinase-independent, engulfment is kinase-dependent); Protein S and Gas6 show extremely rapid binding kinetics to phosphatidylserine-displaying apoptotic cells; Mer-mediated phagocytosis can occur independently of αV integrins.","method":"Kinase-dead Mer mutants, phagocytosis assays, tethering assays, ligand binding kinetics, integrin-blocking experiments","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 / Moderate — kinase-dead mutant dissects tethering from engulfment mechanistically, single lab with multiple orthogonal methods","pmids":["25695599"],"is_preprint":false},{"year":2015,"finding":"MERTK expressed on tolerogenic DCs suppresses T cell activation through competition for PROS1 (Protein S): DC-expressed MERTK acts as a decoy to neutralize PROS1, which otherwise drives an autocrine pro-proliferative MERTK-PROS1 signaling loop in TCR-activated T cells; Mer-Fc protein mimicking DC MERTK suppresses naïve and memory T cell activation.","method":"Neutralization of MERTK in allogeneic MLR, Mer-Fc soluble receptor competition assay, DC-T cell co-cultures, PROS1 blocking","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — soluble receptor competition with functional T cell readouts, single lab, two orthogonal approaches","pmids":["25624460"],"is_preprint":false},{"year":2015,"finding":"Tyro3 gene dosage genetically modifies Mertk-associated retinal degeneration: loss of Tyro3 function accelerates photoreceptor degeneration in Mertk knockout mice; TYRO3 protein co-localizes with nascent photoreceptor outer segment phagosomes in primary RPE cells; Tyro3 expression in RPE is controlled by a cis-acting eQTL with the B6 allele conferring ~3-fold higher expression.","method":"Genetic mapping, Mertk/Tyro3 double-knockout mouse models, immunolocalization, primary RPE phagocytosis assay, Tyro3 overexpression in cultured cells","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (double KO), functional phagocytosis assay, and eQTL analysis, replicated across multiple mouse strains","pmids":["26656104"],"is_preprint":false},{"year":2016,"finding":"MERTK knockdown in prostate cancer cells (but not AXL or TYRO3 knockdown) induces a decreased P-ERK1/2:P-p38 ratio, increased p27, NR2F1, SOX2, and NANOG expression, elevated H3K9me3 and H3K27me3, and G1/G0 arrest—features of cellular dormancy; this is reversed by p38 inhibitor SB203580, implicating MAP kinases in MERTK-dependent dormancy escape.","method":"shRNA and siRNA knockdown, cell cycle analysis, Western blotting for kinase phosphorylation, histone methylation analysis, intra-cardiac injection xenograft model, pharmacological p38 inhibition","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent RNAi approaches with multiple molecular readouts and in vivo validation, single lab","pmids":["27753136"],"is_preprint":false},{"year":2017,"finding":"MERTK cleavage in atherosclerotic lesion macrophages reduces efferocytosis and promotes plaque necrosis and impaired resolution; myeloid-specific expression of a cleavage-resistant MerTK variant in Ldlr-/- mice results in higher macrophage MerTK, lower soluble Mer, improved efferocytosis, smaller necrotic cores, thicker fibrous caps, and increased proresolving lipid mediators.","method":"Cleavage-resistant MerTK knock-in mice (myeloid-specific), atherosclerosis model (fat-fed Ldlr-/- mice), efferocytosis assays, lesion histology, lipid mediator analysis; human carotid plaque correlation","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — cleavage-resistant knock-in with multiple functional readouts in vivo, corroborated with human plaque data","pmids":["28067670"],"is_preprint":false},{"year":2017,"finding":"MerTK crystal structure determined in complex with a macrocyclic pyrimidine inhibitor (UNC2541), showing that macrocycles bind in the ATP-binding pocket of MerTK; structure-based drug design exploiting this binding site yields sub-micromolar inhibitors with MerTK selectivity.","method":"X-ray crystallography of MerTK–inhibitor co-crystal, structure-activity relationship studies, cell-based phospho-ELISA","journal":"ChemMedChem","confidence":"High","confidence_rationale":"Tier 1 / Moderate — X-ray co-crystal structure with SAR validation, single lab","pmids":["28032464"],"is_preprint":false},{"year":2017,"finding":"X-ray co-crystal structure of MerTK complexed with macrocyclic pyrrolopyrimidine inhibitor (UNC3133) shows macrocycles binding in the ATP-binding pocket; cell-based MerTK phosphorylation ELISA confirms sub-40 nM activity.","method":"X-ray crystallography, cell-based MerTK phospho-protein ELISA, structure-activity relationship studies","journal":"ACS medicinal chemistry letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — X-ray co-crystal structure with functional cell-based validation, single lab","pmids":["27994735"],"is_preprint":false},{"year":2017,"finding":"Positive selection in MERTK's signal peptide (G14C mutation) decreases MERTK expression without affecting trafficking or half-life; amino acid substitutions and insertions in the human transmembrane domain create a new self-clustering interaction motif that enhances MERTK avidity, counteracting reduced expression; lower MERTK expression reduces Ebola virus-like particle binding, consistent with antagonistic coevolution against viral hijacking.","method":"Ancestral sequence reconstruction, site-directed mutagenesis, expression analysis, MERTK trafficking/half-life assays, virus-like particle binding assay","journal":"Molecular biology and evolution","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mutagenesis with multiple functional readouts, single lab","pmids":["28369510"],"is_preprint":false},{"year":2018,"finding":"MERTK inhibition (genetic deletion or MRX-2843 small-molecule inhibitor) in the leukemia microenvironment decreases PD-L1 and PD-L2 expression on CD11b+ monocytes/macrophages, indirectly decreases PD-1 on CD4+ and CD8+ T cells, reduces FOXP3+ Tregs, and increases T cell activation, demonstrating that MERTK controls the PD-1 immunosuppressive axis.","method":"Mertk-/- mice, MRX-2843 small-molecule inhibitor, xenograft and syngeneic leukemia mouse models, flow cytometry for immune cell populations and checkpoint marker expression","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic deletion and pharmacological inhibition with consistent immune readouts across multiple models, single lab","pmids":["30385715"],"is_preprint":false},{"year":2018,"finding":"MERTK upregulation mediates intrinsic and adaptive resistance to AXL-targeting agents in HNSCC, TNBC, and NSCLC; ectopic overexpression of MERTK in AXL-inhibitor-sensitive models confers resistance; dual inhibition of AXL and MERTK produces synergistic blockade of downstream signaling and reduced tumor growth in vivo.","method":"AXL inhibitor treatment, siRNA knockdown, MERTK overexpression in sensitive cell lines, patient-derived xenografts, downstream signaling Western blotting, tumor growth in vivo","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with in vivo validation, single lab","pmids":["30093568"],"is_preprint":false},{"year":2019,"finding":"MERTK on activated human CD8+ T cells acts as a late costimulatory receptor: TCR-activated CD8+ T cells express MERTK and the ligand PROS1 from day 2 post-activation; PROS1-mediated MERTK signaling increases proliferation and secretion of effector/memory cytokines; MERTK signaling influences memory CD8+ T cell differentiation; knockdown/inhibition confirmed the costimulatory effect is MERTK-dependent.","method":"Flow cytometry for MERTK/PROS1 expression, MERTK knockdown, pharmacological inhibition, transcriptomic and metabolic analysis, TIL expansion assays with autologous tumor killing","journal":"Cancer immunology research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown and inhibitor confirmation with multiple functional readouts, single lab","pmids":["31266785"],"is_preprint":false},{"year":2019,"finding":"Macrophage MerTK promotes liver fibrosis in NASH via an ERK-TGFβ1 pathway that activates hepatic stellate cells; ADAM17-mediated MerTK cleavage decreases during steatosis-to-NASH transition; mice with a cleavage-resistant MerTK mutant have increased NASH fibrosis; holo- or myeloid-specific Mertk knockout decreases NASH fibrosis.","method":"Mertk knockout mice (holo and myeloid-specific), cleavage-resistant MerTK knock-in, NASH diet models, ERK-TGFβ1 pathway analysis, hepatic stellate cell activation assays","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (KO and cleavage-resistant knock-in) with defined molecular pathway (ERK-TGFβ1) and in vivo fibrosis readouts","pmids":["31839486"],"is_preprint":false},{"year":2019,"finding":"CDCev-derived extracellular vesicles induce sustained MerTK expression in macrophages through transfer of microRNA-26a (which suppresses Adam17, thereby reducing MerTK cleavage), enhancing efferocytosis; cardioprotection by this mechanism is lost in MerTK-deficient animals.","method":"In vitro efferocytosis assays with bone marrow-derived macrophages, microRNA-26a transfer analysis, Adam17 expression, transgenic MerTK-deficient rodent models, single-cell RNA sequencing","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — miRNA mechanism identified with genetic validation in MerTK-KO animals, single lab","pmids":["31434491"],"is_preprint":false},{"year":2020,"finding":"During acute viral infection with VSV, Mertk is activated by apoptotic cells and induces IL-10 and TGF-β production; Mertk-/- mice lack this induction and do not develop innate anergy; mechanistically, Mertk signaling upregulates SOCS1 and SOCS3 to suppress innate immune responses; dexamethasone enhances innate anergy in a Mertk-dependent manner.","method":"Mertk-/- mice, VSV infection model, cytokine measurements (IL-10, TGF-β), SOCS1/SOCS3 expression analysis, dexamethasone treatment","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with specific molecular mechanism (SOCS1/3 upregulation) and pharmacological validation, single lab","pmids":["32187540"],"is_preprint":false},{"year":2020,"finding":"Tim-4 collaborates with Mertk during efferocytosis through a physical interaction between the IgV domain of Tim-4 and the fibronectin type-III domain of Mertk; disruption of this interaction with soluble GST-MertkFnIII abolishes the enhancement of efferocytosis by Mertk in Tim-4-mediated phagocytosis.","method":"Co-immunoprecipitation, immunofluorescence, proximity ligation assay, domain-specific blocking with GST-MertkFnIII, efferocytosis assays","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping and functional blocking assay, single lab","pmids":["32640697"],"is_preprint":false},{"year":2021,"finding":"Mertk kinase activity is essential for efferocytosis: a newly developed kinase-dead Mertk mouse model demonstrates that MERTK kinase activity is required for peritoneal macrophage efferocytosis in vivo; this is conserved in human iPSC-derived macrophages where MERTK blocking antibodies and small molecule inhibitors reduce GAS6-enhanced efferocytosis.","method":"Kinase-dead Mertk knock-in mice, peritoneal efferocytosis assay in vivo, human iPSC-derived macrophages, blocking antibodies, small molecule inhibitors, GAS6 agonism","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 / Strong — kinase-dead mouse model plus human cell validation with multiple independent inhibitory approaches","pmids":["34035216"],"is_preprint":false},{"year":2021,"finding":"Microglial MERTK mediates phosphatidylserine-dependent elimination of inhibitory post-synapses: conditional Cdc50a deletion in neurons induces phosphatidylserine exposure on somas and selective loss of inhibitory post-synapses; ablation of microglia or deletion of microglial Mertk prevents inhibitory post-synapse loss and seizures, establishing MERTK as the microglial phagocytic receptor that recognizes phosphatidylserine on inhibitory post-synapses.","method":"Neuron-specific Cdc50a conditional knockout, microglial ablation, microglial Mertk conditional knockout, synaptic marker quantification, EEG seizure monitoring","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent conditional knockout approaches (microglia depletion and Mertk-specific KO) with specific molecular and behavioral phenotype readouts","pmids":["34013588"],"is_preprint":false},{"year":2021,"finding":"Mertk is required for efficient microglial clearance of myelin debris and subsequent remyelination: Mertk-KO mice show impaired myelin debris clearance and remyelination following demyelination; Mertk-KO brains show attenuated overall microglial response to demyelination but elevated proportion of IFN-responsive microglia; IFNγ further impedes microglial myelin clearance and inhibits oligodendrocyte differentiation downstream of Mertk deficiency.","method":"Mertk knockout mice, cuprizone demyelination model, single-cell RNA sequencing, myelin debris clearance quantification, remyelination histology","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with single-cell transcriptomic characterization and multiple functional readouts, mechanistic IFNγ pathway identified","pmids":["33691116"],"is_preprint":false},{"year":2021,"finding":"ODC-dependent putrescine synthesis maintains basal MerTK expression via a histone methylation-dependent transcriptional mechanism; reduced MerTK in ODC-deficient macrophages impairs MerTK-ERK1/2-dependent IL-10 production upon apoptotic cell exposure; putrescine treatment of ODC-deficient macrophages restores MerTK expression and AC-induced IL-10.","method":"ODC-deficient macrophages, RNA sequencing, ChIP or histone methylation assays, MerTK expression/signaling analysis, zymosan peritonitis model, nanoparticle-mediated ODC silencing in atherosclerosis regression model","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological approach identifying histone methylation as transcriptional regulator of MerTK, multiple models, single lab","pmids":["33406854"],"is_preprint":false},{"year":2021,"finding":"MERTK on mononuclear phagocytes in pancreatic islets promotes T cell regulation by reducing the sensitivity of T cell scanning for cognate antigen, leading to reduced T cell activation and effector function at disease sites; MERTK also regulates T cell arrest in melanoma tumors; loss of mononuclear phagocyte MERTK activity accelerates T cell-mediated islet destruction.","method":"Mertk-/- mice, two-photon intravital imaging of T cell behavior in islets and tumors, type 1 diabetes models, tumor models","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with direct imaging of T cell behavior, single lab","pmids":["34415994"],"is_preprint":false},{"year":2022,"finding":"MERTK interaction with ligand PROS1 in osteoblasts negatively regulates osteoblast differentiation via the VAV2-RHOA-ROCK axis, increasing cell contractility and motility; osteoblast-targeted MERTK deletion increases bone mass; TYRO3 antagonizes this MERTK effect in osteoblasts; pharmacological MERTK blockade (R992) increases osteoblast numbers and bone formation in mice.","method":"Osteoblast-specific Mertk and Tyro3 conditional knockout mice, PROS1 ligand stimulation, VAV2/RHOA/ROCK pathway analysis, pharmacological MERTK inhibitor (R992), bone histomorphometry, cancer bone metastasis models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional knockouts with defined VAV2-RHOA-ROCK pathway mechanism, pharmacological validation, replicated across models","pmids":["36509738"],"is_preprint":false},{"year":2022,"finding":"N-glycosylation of MERTK at asparagine 294 and 454 stabilizes the receptor and promotes oncogenic transformation in hepatocellular carcinoma; non-glycosylated MERTK localizes to the nucleus and is required for HCC cell survival under stress; MERTK ablation increases ROS production and promotes switching from glycolytic to oxidative phosphorylation metabolism.","method":"N-glycosylation site mutagenesis, subcellular fractionation, metabolic assays (glycolysis/OXPHOS), ROS measurement, tumor growth assays","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — site-directed mutagenesis of glycosylation sites with multiple functional readouts including subcellular localization, single lab","pmids":["35728303"],"is_preprint":false},{"year":2022,"finding":"MerTK activation by Gas6 induces MERTK phosphorylation and downstream Akt activation in macrophages; MerTK-activated macrophages produce a secretome (including VEGF-A) that promotes HSC migration, proliferation, viability, and profibrogenic factor expression through STAT3 and p38 signaling in hepatic stellate cells; these effects are specifically blocked by MerTK pharmacologic inhibition (UNC569) or knockdown.","method":"Gas6 stimulation, UNC569 pharmacological inhibition, siRNA knockdown, conditioned medium transfer to HSCs, Boyden chamber migration, BrdU proliferation, STAT3/p38/ERK1/2 Western blotting","journal":"JHEP reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic inhibition with conditioned medium mechanistic approach, single lab","pmids":["35252828"],"is_preprint":false},{"year":2022,"finding":"Arid3a negatively regulates Mertk transcription in macrophages by directly binding to the Mertk promoter (confirmed by ChIP-seq and luciferase reporter assay); Arid3a-deficient macrophages show enhanced Mertk-mediated efferocytosis of apoptotic cholangiocytes; myeloid-specific Arid3a deletion alleviates cholestatic liver injury in a Mertk-dependent manner.","method":"ChIP-seq, luciferase reporter assay, myeloid-specific Arid3a knockout mice, three cholestatic mouse models, Mertk inhibitor (UNC2025) in vivo and in vitro, flow cytometry","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct promoter binding by ChIP-seq plus luciferase reporter, genetic rescue with Mertk inhibitor in vivo, multiple orthogonal methods","pmids":["37659731"],"is_preprint":false},{"year":2022,"finding":"MERTK expressed in endothelial cells maintains endothelial barrier function by regulating adherens junction structure, junction protein levels, and basal Rac1 activity; siRNA knockdown of MERTK in human pulmonary microvascular endothelial cells enhances neutrophil transendothelial migration and increases dextran permeability. However, endothelial cell-specific Mertk deletion in vivo (iEC Mertk-/- mice) did not replicate aggravated inflammation in P. aeruginosa pneumonia.","method":"siRNA knockdown in primary human endothelial cells, dextran permeability assay, Rac1 activity assay, adherens junction analysis, inducible endothelial-specific Mertk-/- mice, in vivo P. aeruginosa pneumonia model","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro mechanism identified (Rac1/adherens junctions) but in vivo endothelial-specific KO did not confirm, partial mechanistic support","pmids":["31805065"],"is_preprint":false},{"year":2023,"finding":"Stress hormones increase MERTK expression in astrocytes through glucocorticoid receptor (GR) activation, driving astrocyte-mediated excitatory post-synapse phagocytosis; early social deprivation activates the GR-MERTK pathway specifically in astrocytes; ablation of GR or MERTK in astrocytes prevents loss of excitatory synapses, abnormal neuronal network activity, and behavioral abnormalities.","method":"Astrocyte-specific conditional knockout of GR and Mertk, in vitro stress hormone treatment, human brain organoid experiments, synapse quantification, EEG, behavioral assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional knockouts with defined GR-MERTK transcriptional pathway, multiple orthogonal readouts including behavioral outcomes","pmids":["37527657"],"is_preprint":false},{"year":2023,"finding":"KLF4 transcription factor mediates training-induced MERTK upregulation in alveolar macrophages; KLF4-driven MERTK expression expands a MERTKhiMarcohiCD163+F4/80low tissue-resident AM subset with enhanced efferocytosis capacity; adoptive transfer of trained AMs restricts inflammatory lung injury.","method":"Transcriptomic analysis, KLF4 ChIP (implied by KLF4 overexpression/knockdown), single-cell mass cytometry, lineage tracing, adoptive transfer experiments","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcription factor identified with functional efferocytosis and adoptive transfer validation, single lab","pmids":["37615937"],"is_preprint":false},{"year":2023,"finding":"EphA4 receptor tyrosine kinase suppresses MERTK expression and efferocytosis in monocytes/macrophages via inhibition of the ERK/Stat6 signaling pathway; loss of EphA4 increases mRNA expression of Mertk and Gas6, enhances efferocytosis, and improves functional outcome after brain injury; selective ERK and Stat6 inhibitors attenuate this effect.","method":"GFP bone marrow chimeric EphA4 knockout mice, single-cell RNAseq, in vitro efferocytosis assay, ERK/Stat6 inhibitors, immunolocalization of p-ERK/p-Stat6 with MERTK","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with pharmacological pathway validation, single lab","pmids":["37941008"],"is_preprint":false},{"year":2024,"finding":"MerTK renders hepatocellular carcinoma resistant to anti-PD-1/PD-L1 therapy by limiting ferroptosis via upregulation of SLC7A11 through the ERK/SP1 pathway, and by facilitating MDSC recruitment to the tumor microenvironment; MerTK inhibition (sitravatinib) sensitizes resistant HCC to anti-PD-L1 by promoting ferroptosis and decreasing MDSC infiltration.","method":"Syngeneic mouse HCC models, MERTK knockdown/overexpression, SLC7A11 expression analysis, ERK/SP1 pathway analysis, MDSC flow cytometry, sitravatinib pharmacological treatment","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological approach in two syngeneic models with defined ERK/SP1/SLC7A11 pathway, single lab","pmids":["38382467"],"is_preprint":false},{"year":2024,"finding":"MERTK is identified as a TGFβ-inducible effector of fibrosis in multiple organs; MERTK induces TGFβ expression and drives TGFβ signaling in a positive feedback loop; MERTK regulates both canonical and noncanonical TGFβ signaling; MERTK increases transcription of fibrosis genes by modulating chromatin accessibility and RNA polymerase II activity; pharmacological MERTK inhibition reduces fibrosis in liver, kidney, and lung mouse models even after fibrosis is established.","method":"Human HSC and macrophage in vitro studies, three mouse fibrosis models (liver, kidney, lung), chromatin accessibility assays, RNA polymerase II activity assays, TGFβ signaling analysis, pharmacological MERTK inhibition","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — defined positive feedback loop with chromatin-level mechanism, replicated across three organ fibrosis models with pharmacological validation","pmids":["38569018"],"is_preprint":false},{"year":2024,"finding":"MerTK mediates non-inflammatory phagocytosis of alpha-synuclein fibrils by human microglia: pharmacological MerTK inhibition and siRNA knockdown both decrease the rate of alpha-synuclein fibril internalization; alpha-synuclein fibril uptake via MerTK does not induce pro-inflammatory cytokines (IL-6, TNF) and downmodulates IL-1β, consistent with non-inflammatory MerTK-mediated phagocytosis.","method":"Human primary and iPSC-derived microglia, pharmacological MerTK inhibition, siRNA knockdown, cytokine secretion assays, fibril internalization quantification","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent inhibitory approaches (pharmacological and siRNA) in human microglia with multiple functional readouts, single lab","pmids":["37671615"],"is_preprint":false},{"year":2024,"finding":"ALKAL1, a target gene of the aryl hydrocarbon receptor (AhR), facilitates MerTK phosphorylation in tumor-associated macrophages, resulting in heightened phagocytic activity and subsequent polarization toward an immunosuppressive phenotype; AhR antagonist delivery to tumor-associated macrophages suppresses MerTK expression and improves anti-PD-L1 efficacy.","method":"Single-cell RNAseq, adoptive transfer of MerTK+ macrophages, mechanistic ALKAL1/AhR studies, AhR antagonist in mannosylated micelles, MerTK phosphorylation assays","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic ALKAL1-AhR-MerTK phosphorylation pathway with functional validation including adoptive transfer, single lab","pmids":["39365866"],"is_preprint":false},{"year":2025,"finding":"Staphylococcus aureus vesicles (SAVs) activate the TLR2-MyD88-p38 MAPK signaling pathway to promote cleavage/shedding of MerTK from macrophage surfaces, thereby inhibiting efferocytosis; selective p38 MAPK inhibition prevents MerTK shedding, restores efferocytosis, and accelerates wound healing.","method":"Purified SAVs, TLR2/MyD88/p38 pathway analysis (Western blot, siRNA), MerTK shedding quantification by flow cytometry and RNA-seq, p38 MAPK inhibitor treatment, in vivo wound healing model","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined TLR2-MyD88-p38-MerTK cleavage axis with siRNA and pharmacological validation in vitro and in vivo, single lab","pmids":["39780180"],"is_preprint":false},{"year":2013,"finding":"UNC1062 is a pyrazolopyrimidine sulfonamide MerTK inhibitor with IC50 = 1.1 nM; in cancer cells it inhibits MerTK phosphorylation and colony formation in soft agar, confirming the functional importance of MerTK kinase activity in oncogenic transformation.","method":"Kinase biochemical assay, cell-based MerTK phosphorylation assay, soft agar colony formation","journal":"European journal of medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with cell-based functional readout, single lab","pmids":["23693152"],"is_preprint":false},{"year":2022,"finding":"BMS794833 inhibits MERTK by binding to both the ATP-binding pocket and an allosteric back pocket (rendering MERTK inactive), as shown by X-ray co-crystal structure; it competitively inhibits MERTK autophosphorylation in macrophages and significantly inhibits macrophage efferocytosis in vitro and in vivo.","method":"X-ray co-crystal structure of BMS794833-MERTK, homogeneous time-resolved fluorescence kinetic assay, Western blotting for MERTK autophosphorylation, real-time efferocytosis monitoring, in vivo mouse efferocytosis model","journal":"Experimental & molecular medicine","confidence":"High","confidence_rationale":"Tier 1 / Moderate — X-ray crystal structure with kinase assay and functional cellular/in vivo validation, single lab","pmids":["36056187"],"is_preprint":false},{"year":2009,"finding":"MerTK promotes macrophage survival following oxidative stress (H2O2): H2O2 triggers Mer phosphorylation in a Gas6-dependent manner; MerTK signaling increases pAkt and pErk1/2 (3-fold and 4.5-fold respectively), decreases PARP and Caspase-3 cleavage, and provides up to 2-fold enhanced survival to macrophages; warfarin or MerFc (blocking Gas6) prevents H2O2-mediated Mer activation.","method":"H2O2 treatment, warfarin/MerFc Gas6 inhibition, Mer knockout macrophages, Western blotting for pAkt/pErk/PARP/Caspase-3, cell viability assay","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ligand-dependence established with multiple inhibitors, Mer KO comparison, specific downstream readouts, single lab","pmids":["19386698"],"is_preprint":false},{"year":2009,"finding":"MerTK in dendritic cells negatively regulates BAFF production: mertk-/- mice contain elevated splenic DCs with elevated proportion of BAFF-secreting cells; mertk-/- BMDCs also have elevated BAFF-secreting cells at rest and after LPS or apoptotic cell stimulation; however, despite more BAFF-secreting cells, mertk-/- BMDCs are not superior at promoting B cell survival.","method":"mertk-/- mice, flow cytometry, BAFF decoy receptor blocking, DC-B cell co-culture survival assay","journal":"Autoimmunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with functional cytokine and cell survival readouts; negative finding on B cell survival is explicitly noted, single lab","pmids":["19301199"],"is_preprint":false},{"year":2022,"finding":"Pentoxifylline (PTX) alleviates ischemic white matter injury through PPAR-γ nuclear translocation, which upregulates Mertk expression in microglia; microglia-specific Mertk knockout blocks the therapeutic effects of PTX in BCAS model; PTX-upregulated Mertk enhances microglial phagocytosis of myelin debris.","method":"BCAS mouse model (bilateral common carotid artery stenosis), microglia-specific Mertk knockout mice, Mertk inhibitor, PPAR-γ inhibitor, immunofluorescence, Western blotting, flow cytometry","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — microglia-specific KO with PPAR-γ inhibitor confirming regulatory pathway, single lab","pmids":["35642056"],"is_preprint":false}],"current_model":"MERTK is a receptor tyrosine kinase that functions as the central mediator of efferocytosis (apoptotic cell clearance) across multiple cell types including macrophages, microglia, astrocytes, retinal pigment epithelium, and platelets; upon binding its vitamin K-dependent bridging ligands Gas6 and Protein S (which engage phosphatidylserine on apoptotic cells), MERTK undergoes autophosphorylation and activates downstream signaling cascades including PI3K/AKT, MAPK/ERK, PLCγ2, JAK/STAT, RHOA-ROCK, and SOCS1/3, driving phagocytic engulfment, cell survival, and anti-inflammatory responses; MERTK surface availability is dynamically regulated by proteolytic shedding (via ADAM17 and ADAM9) that generates a decoy soluble receptor, while its transcription is controlled by KLF4, PPAR-γ, glucocorticoid receptor, and Arid3a; in the CNS, microglial MERTK eliminates phosphatidylserine-displaying inhibitory synapses and myelin debris, and in osteoblasts MERTK-PROS1 signaling negatively regulates bone formation via the VAV2-RHOA-ROCK axis, illustrating tissue-specific functional diversity."},"narrative":{"mechanistic_narrative":"MERTK is a transmembrane receptor tyrosine kinase of the Axl family that serves as a central engulfment receptor coupling recognition of phosphatidylserine on apoptotic cells, debris, and synapses to phagocytic clearance and anti-inflammatory signaling across macrophages, microglia, astrocytes, dendritic cells, retinal pigment epithelium, and platelets [PMID:8086340, PMID:10699188, PMID:25695599]. The receptor carries extracellular immunoglobulin and fibronectin type III domains and an intracellular kinase, and an alternatively spliced soluble form was recognized at cloning [PMID:8086340]. Engulfment is driven by bridging ligands — Gas6, Protein S/PROS1, and the Tubby/Tulp1 proteins — that link MERTK to phosphatidylserine on apoptotic targets, inducing receptor autophosphorylation [PMID:20978472, PMID:25695599]. Ligand binding distinguishes two steps: kinase-independent tethering and kinase-dependent engulfment, the latter shown to be obligatory for efferocytosis in kinase-dead mice and human iPSC-derived macrophages [PMID:25695599, PMID:34035216]. Downstream, MERTK recruits PLCγ2 during apoptotic-cell engulfment [PMID:14704368] and activates PI3K/AKT, MAPK/ERK, JAK/STAT, and STAT6 cascades that promote phagocytosis, cell survival under oxidative stress, and anti-inflammatory cytokine output including IL-10, TGF-β, and SOCS1/3 induction [PMID:23585477, PMID:23474756, PMID:19386698, PMID:32187540]. MERTK surface availability is governed by proteolytic shedding that generates a soluble decoy receptor; cleavage-resistant knock-in models establish that limiting shedding enhances efferocytosis and tissue resolution in atherosclerosis and modulates fibrosis, while pathways acting through ADAM17 (microRNA-26a, TLR2-MyD88-p38) tune shedding up or down [PMID:25538233, PMID:28067670, PMID:31434491, PMID:39780180]. Its transcription is controlled by KLF4, PPAR-γ, the glucocorticoid receptor, and the repressor Arid3a, providing context-specific induction in trained macrophages, microglia, and stress-exposed astrocytes [PMID:37615937, PMID:35642056, PMID:37527657, PMID:37659731]. In the CNS, MERTK mediates phosphatidylserine-dependent elimination of inhibitory and excitatory synapses, clearance of myelin debris during remyelination, and non-inflammatory uptake of alpha-synuclein fibrils [PMID:34013588, PMID:37527657, PMID:33691116, PMID:37671615]. In disease contexts MERTK drives tumor survival, invasion, immune evasion via the PD-1/PD-L1 axis, therapy resistance, and a TGF-β-coupled profibrotic program in liver, kidney, and lung, and in osteoblasts PROS1-MERTK signaling represses bone formation through a VAV2-RHOA-ROCK axis [PMID:23585477, PMID:23474756, PMID:30385715, PMID:38569018, PMID:36509738]. Loss-of-function mutation of Mertk causes failure of RPE phagocytosis of photoreceptor outer segments and retinal degeneration [PMID:10699188].","teleology":[{"year":1994,"claim":"Established MERTK's molecular identity as a novel receptor tyrosine kinase, defining the domain architecture and expression pattern that frame all later mechanistic work.","evidence":"cDNA expression cloning, sequence and domain analysis, Northern blot expression profiling","pmids":["8086340"],"confidence":"High","gaps":["No ligand identified at cloning","Functional role of the truncated soluble splice form not tested","Catalytic activity inferred from sequence motif, not assayed"]},{"year":2000,"claim":"Linked MERTK loss to a defined phagocytic failure in vivo, showing the receptor is essential for RPE clearance of photoreceptor outer segments and causally tied to retinal dystrophy.","evidence":"Positional cloning and genomic deletion mapping in the RCS rat retinal dystrophy model","pmids":["10699188"],"confidence":"High","gaps":["Did not identify the bridging ligands engaging MERTK in RPE","Downstream signaling of phagocytosis unresolved","Generalizability beyond RPE not addressed"]},{"year":2004,"claim":"Connected receptor activation to an immediate phagocytic effector by showing PLCγ2 recruitment and activation downstream of MERTK during apoptotic-cell engulfment.","evidence":"Reciprocal Co-IP and PI-PLC inhibition in peritoneal macrophages and J774 cells","pmids":["14704368"],"confidence":"High","gaps":["Single lab, two cell systems","Direct vs adaptor-mediated MERTK-PLCγ2 interaction not resolved","Link to cytoskeletal engulfment machinery not mapped"]},{"year":2004,"claim":"Extended MERTK function beyond clearance to platelet biology, identifying it as the dominant platelet Gas6 receptor required for aggregation and thrombosis.","evidence":"Mer knockout mice, in vitro aggregation assays, in vivo thrombosis models","pmids":["15130911"],"confidence":"High","gaps":["Platelet-intrinsic signaling pathway not delineated","Whether MERTK acts cell-autonomously in platelets not formally separated"]},{"year":2009,"claim":"Defined MERTK as a pro-survival and immune-regulatory receptor, showing Gas6-dependent activation protects macrophages from oxidative stress and that DC MERTK restrains BAFF production.","evidence":"H2O2 treatment with Gas6 blockade and Mer-KO macrophages; mertk-/- mice with BAFF and B-cell co-culture readouts","pmids":["19386698","19301199"],"confidence":"Medium","gaps":["BAFF effect did not translate to enhanced B-cell survival","AKT/ERK survival readouts single lab","Mechanism linking MERTK to BAFF transcription unresolved"]},{"year":2010,"claim":"Broadened the MERTK ligand repertoire beyond Gas6/Protein S by identifying Tubby and Tulp1 as bridging molecules and mapping their minimal MERTK-binding motifs.","evidence":"Co-IP, receptor phosphorylation, soluble-ectodomain blocking, and domain mutagenesis","pmids":["20978472"],"confidence":"High","gaps":["Physiological tissue context of Tubby/Tulp1-MERTK engagement not established in vivo","Receptor selectivity among TAM members partially overlapping"]},{"year":2012,"claim":"Identified MERTK as a driver of tumor invasion and apoptosis resistance, linking it to actomyosin contractility via myosin light chain 2 phosphorylation in glioblastoma.","evidence":"shRNA knockdown, inactive-mutant overexpression, invasion assays, MLC2 phospho-blotting","pmids":["22469987"],"confidence":"Medium","gaps":["Single lab","Direct kinase substrates upstream of MLC2 not mapped","Ligand dependence in tumor setting not defined"]},{"year":2013,"claim":"Established MERTK as an oncogenic signaling hub in melanoma and AML, mapping Gas6-driven activation to MAPK/ERK, PI3K/AKT, and JAK/STAT prosurvival pathways, and validated kinase activity pharmacologically.","evidence":"Gas6 stimulation with downstream phospho-blotting, shRNA knockdown, xenografts, and the UNC1062 kinase inhibitor","pmids":["23585477","23474756","23617806","23693152"],"confidence":"High","gaps":["Relative contribution of each downstream pathway to tumor phenotype not dissected","CDC42 and AKT dependencies from a single melanoma study"]},{"year":2014,"claim":"Distinguished MERTK's phagocytic and shedding functions, showing it confers efferocytosis and PD-L1/chemoresistance in epithelial/breast cells and that proteolytic shedding produces a decoy soluble receptor limiting RPE phagocytosis.","evidence":"Gain/loss-of-function efferocytosis assays; conditioned-media shedding analysis with metalloprotease inhibitors in RPE","pmids":["25074939","25538233"],"confidence":"Medium","gaps":["Protease identity not definitively assigned in these studies","PD-L1 induction mechanism downstream of MERTK unresolved"]},{"year":2015,"claim":"Mechanistically dissected efferocytosis into kinase-independent tethering and kinase-dependent engulfment, and revealed MERTK as a PROS1 decoy regulating T-cell activation; also defined Tyro3 as a genetic modifier of MERTK retinal function.","evidence":"Kinase-dead Mer mutants and tethering/engulfment assays; Mer-Fc PROS1 competition in DC-T cocultures; Mertk/Tyro3 double-knockout mice with eQTL mapping","pmids":["25695599","25624460","26656104"],"confidence":"High","gaps":["Molecular basis of kinase-independent tethering not resolved","Functional redundancy between TAM receptors context-dependent"]},{"year":2017,"claim":"Provided structural and in vivo proof that MERTK cleavage state governs tissue resolution, and delivered co-crystal structures defining the druggable ATP pocket exploited for selective inhibitors.","evidence":"Cleavage-resistant MerTK knock-in mice in atherosclerosis with human plaque correlation; X-ray co-crystal structures with macrocyclic inhibitors and SAR; evolutionary mutagenesis of signal peptide/TM domain","pmids":["28067670","28032464","27994735","28369510"],"confidence":"High","gaps":["No structure of the ligand-bound ectodomain","Conformational changes on autophosphorylation not captured"]},{"year":2018,"claim":"Positioned MERTK as a node in tumor immune evasion and therapy resistance, controlling the PD-1/PD-L1 axis in the leukemia microenvironment and mediating resistance to AXL-targeted agents.","evidence":"Mertk-/- mice and MRX-2843 inhibitor with immune profiling; AXL-inhibitor models with MERTK overexpression/knockdown and dual inhibition in vivo","pmids":["30385715","30093568"],"confidence":"High","gaps":["Whether checkpoint regulation is efferocytosis-dependent not fully separated","AXL/MERTK cross-resistance mechanism single lab"]},{"year":2019,"claim":"Revealed MERTK's profibrotic and immunoregulatory signaling in tissue contexts, driving NASH fibrosis via ERK-TGFβ1, acting as a CD8 T-cell costimulatory receptor, and being stabilized by extracellular-vesicle microRNA-26a that suppresses ADAM17.","evidence":"Mertk KO and cleavage-resistant knock-in NASH models; CD8 T-cell PROS1/MERTK functional assays; miR-26a/Adam17 EV studies in MerTK-deficient animals","pmids":["31839486","31266785","31434491","31805065"],"confidence":"High","gaps":["Endothelial-specific role not confirmed in vivo","Cell-type origin of profibrotic MERTK signal partially overlapping"]},{"year":2020,"claim":"Defined how MERTK enforces anti-inflammatory tone during viral infection and how its transcription is metabolically and developmentally controlled, linking apoptotic-cell sensing to SOCS1/3-mediated innate anergy and polyamine/ODC-dependent expression.","evidence":"Mertk-/- mice in VSV infection with SOCS1/3 and cytokine readouts; ODC-deficient macrophages with histone-methylation and putrescine rescue","pmids":["32187540","33406854"],"confidence":"Medium","gaps":["Direct transcription factors at the Mertk locus in these contexts not fully identified","Single lab per finding"]},{"year":2021,"claim":"Cemented MERTK as the microglial/astrocytic phagocytic receptor for phosphatidylserine-displaying synapses and myelin debris in the CNS, and confirmed its kinase activity is required for efferocytosis in vivo and in human macrophages.","evidence":"Conditional microglial Mertk KO with synapse and seizure readouts; cuprizone demyelination scRNA-seq; kinase-dead Mertk mice plus human iPSC macrophages; PPAR-γ-PTX microglial KO model","pmids":["34013588","33691116","34035216","35642056","34415994"],"confidence":"High","gaps":["Signals selecting which synapses expose phosphatidylserine partly upstream of MERTK","IFNγ counter-regulation mechanism incompletely mapped"]},{"year":2022,"claim":"Expanded MERTK regulation and tissue function: defined Arid3a as a direct transcriptional repressor, the GR and KLF4 as inducers, a PROS1-VAV2-RHOA-ROCK axis repressing bone formation, an allosteric inhibitor-binding pocket, and N-glycosylation-controlled stability/localization.","evidence":"ChIP-seq and luciferase for Arid3a; cell-type-specific GR/KLF4/osteoblast Mertk conditional KOs; BMS794833 co-crystal structure; glycosylation-site mutagenesis; Tim-4 FnIII-domain Co-IP","pmids":["37659731","37527657","37615937","36509738","36056187","35728303","32640697","35252828"],"confidence":"High","gaps":["Coordination among multiple transcriptional regulators not integrated","Nuclear MERTK function mechanistically unresolved"]},{"year":2024,"claim":"Generalized MERTK as a TGFβ-coupled profibrotic effector acting at the chromatin level across organs and as a multifaceted driver of immunotherapy resistance via ferroptosis suppression, MDSC recruitment, and macrophage polarization.","evidence":"Three-organ fibrosis models with chromatin-accessibility and Pol II assays; HCC syngeneic models with SLC7A11/ERK-SP1 and MDSC analysis; ALKAL1-AhR-MerTK phosphorylation studies; alpha-synuclein fibril uptake in human microglia; S. aureus vesicle TLR2-p38 shedding axis","pmids":["38569018","38382467","39365866","37671615","39780180"],"confidence":"Medium","gaps":["How a surface RTK modulates chromatin accessibility mechanistically not resolved","Several pathways from single labs awaiting independent confirmation"]},{"year":null,"claim":"How MERTK ligand engagement is structurally transduced into the divergent tissue-specific outputs — phagocytic engulfment, prosurvival signaling, profibrotic chromatin remodeling, and bone/synapse suppression — and how the multiple transcriptional and shedding regulators are integrated in a given cell, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No ligand-bound ectodomain structure linking binding to activation","Mechanism by which a membrane RTK alters chromatin accessibility unknown","Integration of KLF4/PPARγ/GR/Arid3a transcriptional inputs uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,12,27,2]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[17,18,46]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[0,12,5,28]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[7,8,47]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,12,11]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[11,1,13]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[33]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,20,25,31]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,8,47,2]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,12,27,28]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[3]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[16,23,41,40]}],"complexes":[],"partners":["GAS6","PROS1","PLCG2","TYRO3","AXL","TIMD4","TULP1","ALKAL1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q12866","full_name":"Tyrosine-protein kinase Mer","aliases":["Proto-oncogene c-Mer","Receptor tyrosine kinase MerTK"],"length_aa":999,"mass_kda":110.2,"function":"Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6. Regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells (efferocytosis). Ligand binding at the cell surface induces autophosphorylation of MERTK on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with GRB2 or PLCG2 and induces phosphorylation of MAPK1, MAPK2, FAK/PTK2 or RAC1. MERTK signaling plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment (PubMed:32640697). Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. Also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q12866/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MERTK","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MERTK","total_profiled":1310},"omim":[{"mim_id":"613862","title":"RETINITIS PIGMENTOSA 38; RP38","url":"https://www.omim.org/entry/613862"},{"mim_id":"612453","title":"MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 10; MEGF10","url":"https://www.omim.org/entry/612453"},{"mim_id":"611768","title":"MICRO RNA 335; MIR335","url":"https://www.omim.org/entry/611768"},{"mim_id":"611767","title":"MICRO RNA 126; MIR126","url":"https://www.omim.org/entry/611767"},{"mim_id":"610359","title":"RETINITIS PIGMENTOSA 33; RP33","url":"https://www.omim.org/entry/610359"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Midbody","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"},{"location":"Acrosome","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"choroid plexus","ntpm":89.9}],"url":"https://www.proteinatlas.org/search/MERTK"},"hgnc":{"alias_symbol":["mer","RP38","c-Eyk","Tyro12"],"prev_symbol":[]},"alphafold":{"accession":"Q12866","domains":[{"cath_id":"2.60.40.10","chopping":"97-195","consensus_level":"high","plddt":80.973,"start":97,"end":195},{"cath_id":"2.60.40.10","chopping":"199-281","consensus_level":"medium","plddt":90.2467,"start":199,"end":281},{"cath_id":"2.60.40.10","chopping":"289-378","consensus_level":"medium","plddt":90.4233,"start":289,"end":378},{"cath_id":"2.60.40.10","chopping":"393-481","consensus_level":"high","plddt":86.3688,"start":393,"end":481},{"cath_id":"3.30.200.20","chopping":"565-673","consensus_level":"high","plddt":83.8595,"start":565,"end":673},{"cath_id":"1.10.510.10","chopping":"679-861","consensus_level":"high","plddt":88.8204,"start":679,"end":861}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12866","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q12866-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q12866-F1-predicted_aligned_error_v6.png","plddt_mean":72.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MERTK","jax_strain_url":"https://www.jax.org/strain/search?query=MERTK"},"sequence":{"accession":"Q12866","fasta_url":"https://rest.uniprot.org/uniprotkb/Q12866.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q12866/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12866"}},"corpus_meta":[{"pmid":"10699188","id":"PMC_10699188","title":"Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat.","date":"2000","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10699188","citation_count":742,"is_preprint":false},{"pmid":"31221805","id":"PMC_31221805","title":"Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis.","date":"2019","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/31221805","citation_count":630,"is_preprint":false},{"pmid":"31088471","id":"PMC_31088471","title":"Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.","date":"2019","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31088471","citation_count":365,"is_preprint":false},{"pmid":"8086340","id":"PMC_8086340","title":"Cloning and mRNA expression analysis of a novel human protooncogene, c-mer.","date":"1994","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/8086340","citation_count":279,"is_preprint":false},{"pmid":"31839486","id":"PMC_31839486","title":"Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis.","date":"2019","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31839486","citation_count":220,"is_preprint":false},{"pmid":"28067670","id":"PMC_28067670","title":"MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28067670","citation_count":214,"is_preprint":false},{"pmid":"21933973","id":"PMC_21933973","title":"Targeting Axl and Mer kinases in cancer.","date":"2011","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21933973","citation_count":190,"is_preprint":false},{"pmid":"19814784","id":"PMC_19814784","title":"Genomic DNA k-mer spectra: models and modalities.","date":"2009","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/19814784","citation_count":149,"is_preprint":false},{"pmid":"20978472","id":"PMC_20978472","title":"Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis.","date":"2010","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/20978472","citation_count":140,"is_preprint":false},{"pmid":"23585477","id":"PMC_23585477","title":"MERTK receptor tyrosine kinase is a therapeutic target in melanoma.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23585477","citation_count":127,"is_preprint":false},{"pmid":"18195070","id":"PMC_18195070","title":"MerTK is required for apoptotic cell-induced T cell tolerance.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18195070","citation_count":117,"is_preprint":false},{"pmid":"23833304","id":"PMC_23833304","title":"Molecular pathways: MERTK signaling in cancer.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23833304","citation_count":109,"is_preprint":false},{"pmid":"12917805","id":"PMC_12917805","title":"Operon mer: bacterial resistance to mercury and potential for bioremediation of contaminated environments.","date":"2003","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/12917805","citation_count":103,"is_preprint":false},{"pmid":"25695599","id":"PMC_25695599","title":"Mer receptor tyrosine kinase mediates both tethering and phagocytosis of apoptotic cells.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25695599","citation_count":102,"is_preprint":false},{"pmid":"33691116","id":"PMC_33691116","title":"Multiple sclerosis risk gene Mertk is required for microglial activation and subsequent remyelination.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33691116","citation_count":99,"is_preprint":false},{"pmid":"23474756","id":"PMC_23474756","title":"Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23474756","citation_count":90,"is_preprint":false},{"pmid":"34013588","id":"PMC_34013588","title":"Microglial MERTK eliminates phosphatidylserine-displaying inhibitory post-synapses.","date":"2021","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/34013588","citation_count":89,"is_preprint":false},{"pmid":"25624460","id":"PMC_25624460","title":"MERTK as negative regulator of human T cell activation.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/25624460","citation_count":86,"is_preprint":false},{"pmid":"25074939","id":"PMC_25074939","title":"Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25074939","citation_count":84,"is_preprint":false},{"pmid":"32417270","id":"PMC_32417270","title":"MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.","date":"2020","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32417270","citation_count":80,"is_preprint":false},{"pmid":"31434491","id":"PMC_31434491","title":"Mechanism of Enhanced MerTK-Dependent Macrophage Efferocytosis by Extracellular Vesicles.","date":"2019","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31434491","citation_count":79,"is_preprint":false},{"pmid":"16652142","id":"PMC_16652142","title":"Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16652142","citation_count":76,"is_preprint":false},{"pmid":"21912976","id":"PMC_21912976","title":"Bacterial mer operon-mediated detoxification of mercurial compounds: a short review.","date":"2011","source":"Archives of microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/21912976","citation_count":74,"is_preprint":false},{"pmid":"38382467","id":"PMC_38382467","title":"Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38382467","citation_count":70,"is_preprint":false},{"pmid":"22469987","id":"PMC_22469987","title":"Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22469987","citation_count":70,"is_preprint":false},{"pmid":"37615937","id":"PMC_37615937","title":"Trained immunity of alveolar macrophages enhances injury resolution via KLF4-MERTK-mediated efferocytosis.","date":"2023","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37615937","citation_count":68,"is_preprint":false},{"pmid":"27753136","id":"PMC_27753136","title":"Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.","date":"2016","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27753136","citation_count":67,"is_preprint":false},{"pmid":"28605477","id":"PMC_28605477","title":"MerTK as a therapeutic target in glioblastoma.","date":"2018","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28605477","citation_count":66,"is_preprint":false},{"pmid":"14704368","id":"PMC_14704368","title":"The receptor tyrosine kinase MerTK activates phospholipase C gamma2 during recognition of apoptotic thymocytes by murine macrophages.","date":"2004","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/14704368","citation_count":64,"is_preprint":false},{"pmid":"15130911","id":"PMC_15130911","title":"Mer receptor tyrosine kinase signaling participates in platelet function.","date":"2004","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15130911","citation_count":64,"is_preprint":false},{"pmid":"35642056","id":"PMC_35642056","title":"Pentoxifylline alleviates ischemic white matter injury through up-regulating Mertk-mediated myelin clearance.","date":"2022","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/35642056","citation_count":63,"is_preprint":false},{"pmid":"30385715","id":"PMC_30385715","title":"MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30385715","citation_count":62,"is_preprint":false},{"pmid":"23693152","id":"PMC_23693152","title":"UNC1062, a new and potent Mer inhibitor.","date":"2013","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23693152","citation_count":60,"is_preprint":false},{"pmid":"37527657","id":"PMC_37527657","title":"Stress induces behavioral abnormalities by increasing expression of phagocytic receptor MERTK in astrocytes to promote synapse phagocytosis.","date":"2023","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/37527657","citation_count":58,"is_preprint":false},{"pmid":"26656104","id":"PMC_26656104","title":"Tyro3 Modulates Mertk-Associated Retinal Degeneration.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26656104","citation_count":58,"is_preprint":false},{"pmid":"25538233","id":"PMC_25538233","title":"Cleavage of Mer tyrosine kinase (MerTK) from the cell surface contributes to the regulation of retinal phagocytosis.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25538233","citation_count":57,"is_preprint":false},{"pmid":"18587056","id":"PMC_18587056","title":"Overexpression of apoptotic cell removal receptor MERTK in alveolar macrophages of cigarette smokers.","date":"2008","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18587056","citation_count":56,"is_preprint":false},{"pmid":"29659094","id":"PMC_29659094","title":"MERTK mutation update in inherited retinal diseases.","date":"2018","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/29659094","citation_count":55,"is_preprint":false},{"pmid":"37354827","id":"PMC_37354827","title":"NOX2 inhibition stabilizes vulnerable plaques by enhancing macrophage efferocytosis via MertK/PI3K/AKT pathway.","date":"2023","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/37354827","citation_count":54,"is_preprint":false},{"pmid":"19386698","id":"PMC_19386698","title":"Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress.","date":"2009","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/19386698","citation_count":52,"is_preprint":false},{"pmid":"30093568","id":"PMC_30093568","title":"MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.","date":"2018","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30093568","citation_count":47,"is_preprint":false},{"pmid":"31266785","id":"PMC_31266785","title":"MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells.","date":"2019","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/31266785","citation_count":47,"is_preprint":false},{"pmid":"23617806","id":"PMC_23617806","title":"MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.","date":"2013","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/23617806","citation_count":46,"is_preprint":false},{"pmid":"35252828","id":"PMC_35252828","title":"Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators.","date":"2022","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35252828","citation_count":45,"is_preprint":false},{"pmid":"33406854","id":"PMC_33406854","title":"ODC (Ornithine Decarboxylase)-Dependent Putrescine Synthesis Maintains MerTK (MER Tyrosine-Protein Kinase) Expression to Drive Resolution.","date":"2021","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33406854","citation_count":45,"is_preprint":false},{"pmid":"38646649","id":"PMC_38646649","title":"Disturbed flow impairs MerTK-mediated efferocytosis in aortic endothelial cells during atherosclerosis.","date":"2024","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/38646649","citation_count":42,"is_preprint":false},{"pmid":"35728303","id":"PMC_35728303","title":"N-glycosylation stabilizes MerTK and promotes hepatocellular carcinoma tumor growth.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/35728303","citation_count":40,"is_preprint":false},{"pmid":"30518232","id":"PMC_30518232","title":"M2C Polarization by Baicalin Enhances Efferocytosis via Upregulation of MERTK Receptor.","date":"2018","source":"The American journal of Chinese medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30518232","citation_count":40,"is_preprint":false},{"pmid":"38614985","id":"PMC_38614985","title":"Targeted delivery of MerTK protein via cell membrane engineered nanoparticle enhances efferocytosis and attenuates atherosclerosis in diabetic ApoE-/- Mice.","date":"2024","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/38614985","citation_count":39,"is_preprint":false},{"pmid":"37120511","id":"PMC_37120511","title":"Elevated expression of macrophage MERTK exhibits profibrotic effects and results in defective regulation of efferocytosis function in pulmonary fibrosis.","date":"2023","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/37120511","citation_count":38,"is_preprint":false},{"pmid":"24846720","id":"PMC_24846720","title":"Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer.","date":"2014","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24846720","citation_count":37,"is_preprint":false},{"pmid":"35969037","id":"PMC_35969037","title":"Tissue-specific modifier alleles determine Mertk loss-of-function traits.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35969037","citation_count":37,"is_preprint":false},{"pmid":"29428392","id":"PMC_29428392","title":"Mer-mediated eosinophil efferocytosis regulates resolution of allergic airway inflammation.","date":"2018","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29428392","citation_count":37,"is_preprint":false},{"pmid":"37659731","id":"PMC_37659731","title":"A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.","date":"2023","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/37659731","citation_count":34,"is_preprint":false},{"pmid":"37941008","id":"PMC_37941008","title":"Efferocytosis is restricted by axon guidance molecule EphA4 via ERK/Stat6/MERTK signaling following brain injury.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37941008","citation_count":33,"is_preprint":false},{"pmid":"34035216","id":"PMC_34035216","title":"Ligand-dependent kinase activity of MERTK drives efferocytosis in human iPSC-derived macrophages.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34035216","citation_count":32,"is_preprint":false},{"pmid":"26427420","id":"PMC_26427420","title":"A Comprehensive Review of Mutations in the MERTK Proto-Oncogene.","date":"2016","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/26427420","citation_count":32,"is_preprint":false},{"pmid":"18815424","id":"PMC_18815424","title":"Novel splice donor site mutation in MERTK gene associated with retinitis pigmentosa.","date":"2008","source":"The British journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/18815424","citation_count":31,"is_preprint":false},{"pmid":"36509738","id":"PMC_36509738","title":"Regulation of bone homeostasis by MERTK and TYRO3.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36509738","citation_count":30,"is_preprint":false},{"pmid":"34830794","id":"PMC_34830794","title":"Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34830794","citation_count":29,"is_preprint":false},{"pmid":"28032464","id":"PMC_28032464","title":"Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors.","date":"2017","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/28032464","citation_count":29,"is_preprint":false},{"pmid":"31805065","id":"PMC_31805065","title":"The role of endothelial MERTK during the inflammatory response in lungs.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31805065","citation_count":29,"is_preprint":false},{"pmid":"30133807","id":"PMC_30133807","title":"Receptor tyrosine kinase MerTK suppresses an allogenic type I IFN response to promote transplant tolerance.","date":"2018","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/30133807","citation_count":28,"is_preprint":false},{"pmid":"26427450","id":"PMC_26427450","title":"Gene Therapy for MERTK-Associated Retinal Degenerations.","date":"2016","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/26427450","citation_count":28,"is_preprint":false},{"pmid":"38569018","id":"PMC_38569018","title":"Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease.","date":"2024","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38569018","citation_count":27,"is_preprint":false},{"pmid":"35636929","id":"PMC_35636929","title":"Mertk: An emerging target in cancer biology and immuno-oncology.","date":"2022","source":"International review of cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35636929","citation_count":27,"is_preprint":false},{"pmid":"32640697","id":"PMC_32640697","title":"Mertk Interacts with Tim-4 to Enhance Tim-4-Mediated Efferocytosis.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32640697","citation_count":27,"is_preprint":false},{"pmid":"32311417","id":"PMC_32311417","title":"Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy.","date":"2020","source":"International journal of radiation oncology, biology, physics","url":"https://pubmed.ncbi.nlm.nih.gov/32311417","citation_count":27,"is_preprint":false},{"pmid":"27994735","id":"PMC_27994735","title":"Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.","date":"2016","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27994735","citation_count":27,"is_preprint":false},{"pmid":"38493215","id":"PMC_38493215","title":"Axl and MerTK regulate synovial inflammation and are modulated by IL-6 inhibition in rheumatoid arthritis.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38493215","citation_count":26,"is_preprint":false},{"pmid":"27783662","id":"PMC_27783662","title":"MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27783662","citation_count":26,"is_preprint":false},{"pmid":"37846049","id":"PMC_37846049","title":"PanKmer: k-mer-based and reference-free pangenome analysis.","date":"2023","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37846049","citation_count":25,"is_preprint":false},{"pmid":"37671615","id":"PMC_37671615","title":"MerTK is a mediator of alpha-synuclein fibril uptake by human microglia.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37671615","citation_count":25,"is_preprint":false},{"pmid":"34074493","id":"PMC_34074493","title":"Tyro3, Axl, Mertk receptor-mediated efferocytosis and immune regulation in the tumor environment.","date":"2021","source":"International review of cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34074493","citation_count":24,"is_preprint":false},{"pmid":"39365866","id":"PMC_39365866","title":"MerTK+ macrophages promote melanoma progression and immunotherapy resistance through AhR-ALKAL1 activation.","date":"2024","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/39365866","citation_count":23,"is_preprint":false},{"pmid":"30541554","id":"PMC_30541554","title":"Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.","date":"2018","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/30541554","citation_count":22,"is_preprint":false},{"pmid":"38341954","id":"PMC_38341954","title":"Big data analytics for MerTK genomics reveals its double-edged sword functions in human diseases.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38341954","citation_count":21,"is_preprint":false},{"pmid":"29285287","id":"PMC_29285287","title":"MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29285287","citation_count":21,"is_preprint":false},{"pmid":"32187540","id":"PMC_32187540","title":"Dead Cells Induce Innate Anergy via Mertk after Acute Viral Infection.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32187540","citation_count":21,"is_preprint":false},{"pmid":"29553850","id":"PMC_29553850","title":"MerTK mediates STAT3-KRAS/SRC-signaling axis for glioma stem cell maintenance.","date":"2018","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/29553850","citation_count":20,"is_preprint":false},{"pmid":"36056187","id":"PMC_36056187","title":"BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity.","date":"2022","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36056187","citation_count":20,"is_preprint":false},{"pmid":"27081701","id":"PMC_27081701","title":"MERTK as a novel therapeutic target in head and neck cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27081701","citation_count":20,"is_preprint":false},{"pmid":"37926818","id":"PMC_37926818","title":"Mertk-expressing microglia influence oligodendrogenesis and myelin modelling in the CNS.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37926818","citation_count":19,"is_preprint":false},{"pmid":"28462455","id":"PMC_28462455","title":"A novel MERTK mutation causing retinitis pigmentosa.","date":"2017","source":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","url":"https://pubmed.ncbi.nlm.nih.gov/28462455","citation_count":19,"is_preprint":false},{"pmid":"31042769","id":"PMC_31042769","title":"Csf1r or Mer inhibition delays liver regeneration via suppression of Kupffer cells.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31042769","citation_count":19,"is_preprint":false},{"pmid":"34010608","id":"PMC_34010608","title":"MerTK inhibits the activation of the NLRP3 inflammasome after subarachnoid hemorrhage by inducing autophagy.","date":"2021","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/34010608","citation_count":19,"is_preprint":false},{"pmid":"34415994","id":"PMC_34415994","title":"MERTK on mononuclear phagocytes regulates T cell antigen recognition at autoimmune and tumor sites.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34415994","citation_count":18,"is_preprint":false},{"pmid":"19301199","id":"PMC_19301199","title":"The receptor tyrosine kinase MerTK regulates dendritic cell production of BAFF.","date":"2009","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/19301199","citation_count":18,"is_preprint":false},{"pmid":"39742469","id":"PMC_39742469","title":"NLRP3 inflammasome constrains liver regeneration through impairing MerTK-mediated macrophage efferocytosis.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/39742469","citation_count":17,"is_preprint":false},{"pmid":"38386777","id":"PMC_38386777","title":"Tissue-Resident Alveolar Macrophages Reduce Ozone-induced Inflammation via MerTK-mediated Efferocytosis.","date":"2024","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38386777","citation_count":17,"is_preprint":false},{"pmid":"39628480","id":"PMC_39628480","title":"Ozone promotes macrophage efferocytosis and alleviates neuropathic pain by activating the AMPK/Gas6-MerTK/SOCS3 signaling pathway.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39628480","citation_count":16,"is_preprint":false},{"pmid":"37537628","id":"PMC_37537628","title":"Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis.","date":"2023","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/37537628","citation_count":15,"is_preprint":false},{"pmid":"27558819","id":"PMC_27558819","title":"Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?","date":"2016","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/27558819","citation_count":15,"is_preprint":false},{"pmid":"32540991","id":"PMC_32540991","title":"Vitamin D Regulates MerTK-Dependent Phagocytosis in Human Myeloid Cells.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32540991","citation_count":15,"is_preprint":false},{"pmid":"38066599","id":"PMC_38066599","title":"Ozone alleviates MSU-induced acute gout pain via upregulating AMPK/GAS6/MerTK/SOCS3 signaling pathway.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38066599","citation_count":15,"is_preprint":false},{"pmid":"39890468","id":"PMC_39890468","title":"k-mer approaches for biodiversity genomics.","date":"2025","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/39890468","citation_count":14,"is_preprint":false},{"pmid":"28369510","id":"PMC_28369510","title":"Antagonistic Coevolution of MER Tyrosine Kinase Expression and Function.","date":"2017","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/28369510","citation_count":14,"is_preprint":false},{"pmid":"35163068","id":"PMC_35163068","title":"High Glucose Impairs Expression and Activation of MerTK in ARPE-19 Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163068","citation_count":13,"is_preprint":false},{"pmid":"39780180","id":"PMC_39780180","title":"Staphylococcus aureus vesicles impair cutaneous wound healing through p38 MAPK-MerTK cleavage-mediated inhibition of macrophage efferocytosis.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/39780180","citation_count":13,"is_preprint":false},{"pmid":"37644281","id":"PMC_37644281","title":"Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer.","date":"2023","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37644281","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51127,"output_tokens":13387,"usd":0.177093,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":25294,"output_tokens":6450,"usd":0.14386,"stage2_stop_reason":"end_turn"},"total_usd":0.320953,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Mutation/deletion of the Mertk gene (disrupting the splice acceptor site upstream of the second coding exon) in RCS rats causes failure of retinal pigment epithelial (RPE) cells to phagocytose shed photoreceptor outer segments, establishing MERTK as a receptor tyrosine kinase essential for this specialized phagocytic process.\",\n      \"method\": \"Positional cloning, genomic deletion mapping, transcript analysis, genetic concordance in RCS rat retinal dystrophy model\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — positional cloning with functional concordance, replicated across multiple subsequent studies confirming the same mechanism\",\n      \"pmids\": [\"10699188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"MERTK (c-mer) encodes a novel 984-amino acid transmembrane receptor tyrosine kinase with extracellular immunoglobulin and fibronectin type III domains and the kinase signature KWIAIES, classified in the Axl family; it is expressed in peripheral blood monocytes and certain neoplastic lymphocyte lines but not in normal B- and T-lymphocytes. An alternatively spliced transcript encoding a truncated, potentially soluble receptor was also identified.\",\n      \"method\": \"Anti-phosphotyrosine antibody screening of cDNA expression library, sequence analysis, Northern blot RNA expression analysis\",\n      \"journal\": \"Cell growth & differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — original molecular cloning with domain characterization; foundational discovery replicated widely\",\n      \"pmids\": [\"8086340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MerTK activates phospholipase C gamma2 (PLCγ2) during macrophage phagocytosis of apoptotic thymocytes: exposure to apoptotic cells induces tyrosine phosphorylation of MerTK, association of PLCγ2 with MerTK, and phosphorylation of PLCγ2; PI-PLC inhibition blocks phagocytosis without impairing adhesion.\",\n      \"method\": \"Western blotting, immunoprecipitation (Co-IP), antibody cross-linking, pharmacological inhibition of PI-PLC (Et-18-OCH3, U73122) in peritoneal macrophages and J774 cells\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus functional inhibitor assays, two cell systems, single lab\",\n      \"pmids\": [\"14704368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Mer (MERTK) is the predominant Gas6 receptor expressed in mouse and human platelets (Axl and Rse not detected); Mer-deficient mice show decreased platelet aggregation in response to collagen, U46619, and PAR4 agonist, and are protected from collagen/epinephrine-induced pulmonary thromboembolism and ferric chloride-induced thrombosis in vivo, establishing a role for MERTK in platelet function and thrombosis.\",\n      \"method\": \"RT-PCR, Western blot, targeted gene disruption (Mer knockout mice), in vitro platelet aggregation assays, in vivo thrombosis models\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with multiple in vitro and in vivo phenotypic readouts, single lab\",\n      \"pmids\": [\"15130911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MerTK on dendritic cells (DCs) mediates apoptotic cell (AC)-induced inhibition of DC activation/maturation in a Gas6-dependent manner; DCs lacking MerTK kinase activity (NOD.MerTK(KD/KD)) are resistant to AC-induced suppression of proinflammatory cytokines and costimulatory molecule up-regulation, and mice lacking MerTK kinase activity show exacerbated autoimmune diabetes with increased activated pancreatic DCs.\",\n      \"method\": \"Kinase-dead knock-in mice, DC-T cell co-culture, cytokine secretion assays, adoptive transfer, streptozotocin-induced beta cell apoptosis model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — kinase-dead knock-in with multiple functional readouts (cytokine, costimulatory molecule, diabetes model), single lab with multiple orthogonal methods\",\n      \"pmids\": [\"18195070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Tubby and Tulp1 are novel MerTK ligands that act as bridging molecules for phagocytosis: tubby binds only MerTK while Tulp1 binds Tyro3, Axl, and MerTK; both ligands induce MerTK receptor phosphorylation and downstream signaling including non-muscle myosin II redistribution and co-localization with phagosomes; excess soluble MerTK extracellular domain blocks tubby/Tulp1-mediated phagocytosis; five minimal phagocytic determinants (K/R(X)(1-2)KKK) in Tulp1 N-terminus were defined as essential MerTK-binding motifs.\",\n      \"method\": \"Co-immunoprecipitation, receptor phosphorylation assays, blocking with soluble MerTK extracellular domain, phagocytosis assays, domain mapping by mutagenesis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — receptor binding confirmed by Co-IP with domain mutagenesis and functional phagocytosis blocking, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"20978472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MERTK overexpression in glioblastoma multiforme is associated with invasiveness; MERTK depletion disrupts rounded glioma cell morphology, decreases invasive capacity, and reduces expression and phosphorylation of myosin light chain 2, implicating actomyosin contractility as a downstream effector; MERTK also protects cells from DNA-damage-induced apoptosis in a kinase-activity-dependent manner.\",\n      \"method\": \"shRNA knockdown, overexpression of inactive MERTK mutant, invasion assays, Western blotting for myosin light chain 2 phosphorylation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and dominant-negative approaches with specific molecular readout (MLC2 phosphorylation), single lab\",\n      \"pmids\": [\"22469987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In melanoma cells, GAS6 stimulation of MERTK activates MAPK/ERK, PI3K/AKT, and JAK/STAT downstream signaling pathways; shRNA-mediated MERTK inhibition reduces colony formation by up to 59% and diminishes tumor volume by 60% in xenograft models.\",\n      \"method\": \"GAS6 stimulation, Western blotting for downstream pathway phosphorylation, shRNA knockdown, soft agar colony formation, murine xenograft models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ligand stimulation with downstream signaling readouts plus loss-of-function in vitro and in vivo, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23585477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In AML cells, Gas6-stimulated MERTK activates prosurvival and proliferative signaling including phosphorylation of ERK1/2, p38, MSK1, CREB, ATF1, AKT, and STAT6; shRNA knockdown of MERTK increases myeloblast apoptosis 2-3-fold and decreases colony formation by 67-87%; MERTK knockdown prolongs survival in NOD-SCID-gamma xenograft mice.\",\n      \"method\": \"Gas6 ligand stimulation, Western blotting for signaling intermediates, shRNA knockdown, apoptosis assays, colony formation, murine xenograft model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ligand-stimulated signaling plus genetic loss-of-function in vitro and in vivo, single lab with multiple methods\",\n      \"pmids\": [\"23474756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In melanoma, shRNA-mediated MERTK knockdown reduces colony formation and cell migration in a CDC42-dependent manner and decreases cell survival in an AKT-dependent manner; a novel kinase-domain mutation MERTK(P802S) increases cell motility relative to wild-type MERTK.\",\n      \"method\": \"shRNA knockdown, colony formation assay, migration assay, small GTPase dependency experiments, site-directed mutagenesis\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown and mutant overexpression with specific pathway readouts, single lab\",\n      \"pmids\": [\"23617806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MERTK overexpression in MCF10A epithelial cells stimulates efferocytosis in a gain-of-function capacity that is highly dependent on apoptotic cells (phosphatidylserine interface), also stimulates AKT-mediated chemoresistance, and promotes PD-L1 expression through apoptotic cell engagement; knockdown of MERTK in MDA-MB-231 breast cancer cells reduces efferocytosis.\",\n      \"method\": \"Stable MERTK overexpression, shRNA knockdown, efferocytosis assays, AKT pathway assays, PD-L1 expression analysis, soluble TAM receptor blocking\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function in multiple cell lines with functional efferocytosis readouts, single lab\",\n      \"pmids\": [\"25074939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MERTK undergoes proteolytic cleavage to release a soluble sMerTK form from RPE cells; sMerTK acts as a decoy receptor blocking MerTK ligands and thereby limiting phagocytic outer segment binding; blocking MERTK cleavage increases POS binding; MFG-E8 (integrin ligand) markedly increases both phagocytosis and sMerTK shedding.\",\n      \"method\": \"Conditioned media analysis, RPE-J cell phagocytosis assays, metalloprotease inhibitors, MERTK cleavage blocking reagents, interphotoreceptor matrix analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional shedding assays with receptor blocking and in vivo retinal verification, single lab\",\n      \"pmids\": [\"25538233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Mer receptor mediates both tethering and phagocytosis of apoptotic cells by macrophages; Mer-mediated tethering and subsequent AC engulfment can be distinguished by their differential requirement for Mer kinase activity (tethering is kinase-independent, engulfment is kinase-dependent); Protein S and Gas6 show extremely rapid binding kinetics to phosphatidylserine-displaying apoptotic cells; Mer-mediated phagocytosis can occur independently of αV integrins.\",\n      \"method\": \"Kinase-dead Mer mutants, phagocytosis assays, tethering assays, ligand binding kinetics, integrin-blocking experiments\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — kinase-dead mutant dissects tethering from engulfment mechanistically, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"25695599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MERTK expressed on tolerogenic DCs suppresses T cell activation through competition for PROS1 (Protein S): DC-expressed MERTK acts as a decoy to neutralize PROS1, which otherwise drives an autocrine pro-proliferative MERTK-PROS1 signaling loop in TCR-activated T cells; Mer-Fc protein mimicking DC MERTK suppresses naïve and memory T cell activation.\",\n      \"method\": \"Neutralization of MERTK in allogeneic MLR, Mer-Fc soluble receptor competition assay, DC-T cell co-cultures, PROS1 blocking\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — soluble receptor competition with functional T cell readouts, single lab, two orthogonal approaches\",\n      \"pmids\": [\"25624460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Tyro3 gene dosage genetically modifies Mertk-associated retinal degeneration: loss of Tyro3 function accelerates photoreceptor degeneration in Mertk knockout mice; TYRO3 protein co-localizes with nascent photoreceptor outer segment phagosomes in primary RPE cells; Tyro3 expression in RPE is controlled by a cis-acting eQTL with the B6 allele conferring ~3-fold higher expression.\",\n      \"method\": \"Genetic mapping, Mertk/Tyro3 double-knockout mouse models, immunolocalization, primary RPE phagocytosis assay, Tyro3 overexpression in cultured cells\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (double KO), functional phagocytosis assay, and eQTL analysis, replicated across multiple mouse strains\",\n      \"pmids\": [\"26656104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MERTK knockdown in prostate cancer cells (but not AXL or TYRO3 knockdown) induces a decreased P-ERK1/2:P-p38 ratio, increased p27, NR2F1, SOX2, and NANOG expression, elevated H3K9me3 and H3K27me3, and G1/G0 arrest—features of cellular dormancy; this is reversed by p38 inhibitor SB203580, implicating MAP kinases in MERTK-dependent dormancy escape.\",\n      \"method\": \"shRNA and siRNA knockdown, cell cycle analysis, Western blotting for kinase phosphorylation, histone methylation analysis, intra-cardiac injection xenograft model, pharmacological p38 inhibition\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent RNAi approaches with multiple molecular readouts and in vivo validation, single lab\",\n      \"pmids\": [\"27753136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MERTK cleavage in atherosclerotic lesion macrophages reduces efferocytosis and promotes plaque necrosis and impaired resolution; myeloid-specific expression of a cleavage-resistant MerTK variant in Ldlr-/- mice results in higher macrophage MerTK, lower soluble Mer, improved efferocytosis, smaller necrotic cores, thicker fibrous caps, and increased proresolving lipid mediators.\",\n      \"method\": \"Cleavage-resistant MerTK knock-in mice (myeloid-specific), atherosclerosis model (fat-fed Ldlr-/- mice), efferocytosis assays, lesion histology, lipid mediator analysis; human carotid plaque correlation\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cleavage-resistant knock-in with multiple functional readouts in vivo, corroborated with human plaque data\",\n      \"pmids\": [\"28067670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MerTK crystal structure determined in complex with a macrocyclic pyrimidine inhibitor (UNC2541), showing that macrocycles bind in the ATP-binding pocket of MerTK; structure-based drug design exploiting this binding site yields sub-micromolar inhibitors with MerTK selectivity.\",\n      \"method\": \"X-ray crystallography of MerTK–inhibitor co-crystal, structure-activity relationship studies, cell-based phospho-ELISA\",\n      \"journal\": \"ChemMedChem\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — X-ray co-crystal structure with SAR validation, single lab\",\n      \"pmids\": [\"28032464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"X-ray co-crystal structure of MerTK complexed with macrocyclic pyrrolopyrimidine inhibitor (UNC3133) shows macrocycles binding in the ATP-binding pocket; cell-based MerTK phosphorylation ELISA confirms sub-40 nM activity.\",\n      \"method\": \"X-ray crystallography, cell-based MerTK phospho-protein ELISA, structure-activity relationship studies\",\n      \"journal\": \"ACS medicinal chemistry letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — X-ray co-crystal structure with functional cell-based validation, single lab\",\n      \"pmids\": [\"27994735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Positive selection in MERTK's signal peptide (G14C mutation) decreases MERTK expression without affecting trafficking or half-life; amino acid substitutions and insertions in the human transmembrane domain create a new self-clustering interaction motif that enhances MERTK avidity, counteracting reduced expression; lower MERTK expression reduces Ebola virus-like particle binding, consistent with antagonistic coevolution against viral hijacking.\",\n      \"method\": \"Ancestral sequence reconstruction, site-directed mutagenesis, expression analysis, MERTK trafficking/half-life assays, virus-like particle binding assay\",\n      \"journal\": \"Molecular biology and evolution\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with multiple functional readouts, single lab\",\n      \"pmids\": [\"28369510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MERTK inhibition (genetic deletion or MRX-2843 small-molecule inhibitor) in the leukemia microenvironment decreases PD-L1 and PD-L2 expression on CD11b+ monocytes/macrophages, indirectly decreases PD-1 on CD4+ and CD8+ T cells, reduces FOXP3+ Tregs, and increases T cell activation, demonstrating that MERTK controls the PD-1 immunosuppressive axis.\",\n      \"method\": \"Mertk-/- mice, MRX-2843 small-molecule inhibitor, xenograft and syngeneic leukemia mouse models, flow cytometry for immune cell populations and checkpoint marker expression\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic deletion and pharmacological inhibition with consistent immune readouts across multiple models, single lab\",\n      \"pmids\": [\"30385715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MERTK upregulation mediates intrinsic and adaptive resistance to AXL-targeting agents in HNSCC, TNBC, and NSCLC; ectopic overexpression of MERTK in AXL-inhibitor-sensitive models confers resistance; dual inhibition of AXL and MERTK produces synergistic blockade of downstream signaling and reduced tumor growth in vivo.\",\n      \"method\": \"AXL inhibitor treatment, siRNA knockdown, MERTK overexpression in sensitive cell lines, patient-derived xenografts, downstream signaling Western blotting, tumor growth in vivo\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with in vivo validation, single lab\",\n      \"pmids\": [\"30093568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MERTK on activated human CD8+ T cells acts as a late costimulatory receptor: TCR-activated CD8+ T cells express MERTK and the ligand PROS1 from day 2 post-activation; PROS1-mediated MERTK signaling increases proliferation and secretion of effector/memory cytokines; MERTK signaling influences memory CD8+ T cell differentiation; knockdown/inhibition confirmed the costimulatory effect is MERTK-dependent.\",\n      \"method\": \"Flow cytometry for MERTK/PROS1 expression, MERTK knockdown, pharmacological inhibition, transcriptomic and metabolic analysis, TIL expansion assays with autologous tumor killing\",\n      \"journal\": \"Cancer immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown and inhibitor confirmation with multiple functional readouts, single lab\",\n      \"pmids\": [\"31266785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Macrophage MerTK promotes liver fibrosis in NASH via an ERK-TGFβ1 pathway that activates hepatic stellate cells; ADAM17-mediated MerTK cleavage decreases during steatosis-to-NASH transition; mice with a cleavage-resistant MerTK mutant have increased NASH fibrosis; holo- or myeloid-specific Mertk knockout decreases NASH fibrosis.\",\n      \"method\": \"Mertk knockout mice (holo and myeloid-specific), cleavage-resistant MerTK knock-in, NASH diet models, ERK-TGFβ1 pathway analysis, hepatic stellate cell activation assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (KO and cleavage-resistant knock-in) with defined molecular pathway (ERK-TGFβ1) and in vivo fibrosis readouts\",\n      \"pmids\": [\"31839486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDCev-derived extracellular vesicles induce sustained MerTK expression in macrophages through transfer of microRNA-26a (which suppresses Adam17, thereby reducing MerTK cleavage), enhancing efferocytosis; cardioprotection by this mechanism is lost in MerTK-deficient animals.\",\n      \"method\": \"In vitro efferocytosis assays with bone marrow-derived macrophages, microRNA-26a transfer analysis, Adam17 expression, transgenic MerTK-deficient rodent models, single-cell RNA sequencing\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — miRNA mechanism identified with genetic validation in MerTK-KO animals, single lab\",\n      \"pmids\": [\"31434491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"During acute viral infection with VSV, Mertk is activated by apoptotic cells and induces IL-10 and TGF-β production; Mertk-/- mice lack this induction and do not develop innate anergy; mechanistically, Mertk signaling upregulates SOCS1 and SOCS3 to suppress innate immune responses; dexamethasone enhances innate anergy in a Mertk-dependent manner.\",\n      \"method\": \"Mertk-/- mice, VSV infection model, cytokine measurements (IL-10, TGF-β), SOCS1/SOCS3 expression analysis, dexamethasone treatment\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with specific molecular mechanism (SOCS1/3 upregulation) and pharmacological validation, single lab\",\n      \"pmids\": [\"32187540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Tim-4 collaborates with Mertk during efferocytosis through a physical interaction between the IgV domain of Tim-4 and the fibronectin type-III domain of Mertk; disruption of this interaction with soluble GST-MertkFnIII abolishes the enhancement of efferocytosis by Mertk in Tim-4-mediated phagocytosis.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, proximity ligation assay, domain-specific blocking with GST-MertkFnIII, efferocytosis assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping and functional blocking assay, single lab\",\n      \"pmids\": [\"32640697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Mertk kinase activity is essential for efferocytosis: a newly developed kinase-dead Mertk mouse model demonstrates that MERTK kinase activity is required for peritoneal macrophage efferocytosis in vivo; this is conserved in human iPSC-derived macrophages where MERTK blocking antibodies and small molecule inhibitors reduce GAS6-enhanced efferocytosis.\",\n      \"method\": \"Kinase-dead Mertk knock-in mice, peritoneal efferocytosis assay in vivo, human iPSC-derived macrophages, blocking antibodies, small molecule inhibitors, GAS6 agonism\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — kinase-dead mouse model plus human cell validation with multiple independent inhibitory approaches\",\n      \"pmids\": [\"34035216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Microglial MERTK mediates phosphatidylserine-dependent elimination of inhibitory post-synapses: conditional Cdc50a deletion in neurons induces phosphatidylserine exposure on somas and selective loss of inhibitory post-synapses; ablation of microglia or deletion of microglial Mertk prevents inhibitory post-synapse loss and seizures, establishing MERTK as the microglial phagocytic receptor that recognizes phosphatidylserine on inhibitory post-synapses.\",\n      \"method\": \"Neuron-specific Cdc50a conditional knockout, microglial ablation, microglial Mertk conditional knockout, synaptic marker quantification, EEG seizure monitoring\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent conditional knockout approaches (microglia depletion and Mertk-specific KO) with specific molecular and behavioral phenotype readouts\",\n      \"pmids\": [\"34013588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Mertk is required for efficient microglial clearance of myelin debris and subsequent remyelination: Mertk-KO mice show impaired myelin debris clearance and remyelination following demyelination; Mertk-KO brains show attenuated overall microglial response to demyelination but elevated proportion of IFN-responsive microglia; IFNγ further impedes microglial myelin clearance and inhibits oligodendrocyte differentiation downstream of Mertk deficiency.\",\n      \"method\": \"Mertk knockout mice, cuprizone demyelination model, single-cell RNA sequencing, myelin debris clearance quantification, remyelination histology\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with single-cell transcriptomic characterization and multiple functional readouts, mechanistic IFNγ pathway identified\",\n      \"pmids\": [\"33691116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ODC-dependent putrescine synthesis maintains basal MerTK expression via a histone methylation-dependent transcriptional mechanism; reduced MerTK in ODC-deficient macrophages impairs MerTK-ERK1/2-dependent IL-10 production upon apoptotic cell exposure; putrescine treatment of ODC-deficient macrophages restores MerTK expression and AC-induced IL-10.\",\n      \"method\": \"ODC-deficient macrophages, RNA sequencing, ChIP or histone methylation assays, MerTK expression/signaling analysis, zymosan peritonitis model, nanoparticle-mediated ODC silencing in atherosclerosis regression model\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological approach identifying histone methylation as transcriptional regulator of MerTK, multiple models, single lab\",\n      \"pmids\": [\"33406854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MERTK on mononuclear phagocytes in pancreatic islets promotes T cell regulation by reducing the sensitivity of T cell scanning for cognate antigen, leading to reduced T cell activation and effector function at disease sites; MERTK also regulates T cell arrest in melanoma tumors; loss of mononuclear phagocyte MERTK activity accelerates T cell-mediated islet destruction.\",\n      \"method\": \"Mertk-/- mice, two-photon intravital imaging of T cell behavior in islets and tumors, type 1 diabetes models, tumor models\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with direct imaging of T cell behavior, single lab\",\n      \"pmids\": [\"34415994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MERTK interaction with ligand PROS1 in osteoblasts negatively regulates osteoblast differentiation via the VAV2-RHOA-ROCK axis, increasing cell contractility and motility; osteoblast-targeted MERTK deletion increases bone mass; TYRO3 antagonizes this MERTK effect in osteoblasts; pharmacological MERTK blockade (R992) increases osteoblast numbers and bone formation in mice.\",\n      \"method\": \"Osteoblast-specific Mertk and Tyro3 conditional knockout mice, PROS1 ligand stimulation, VAV2/RHOA/ROCK pathway analysis, pharmacological MERTK inhibitor (R992), bone histomorphometry, cancer bone metastasis models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional knockouts with defined VAV2-RHOA-ROCK pathway mechanism, pharmacological validation, replicated across models\",\n      \"pmids\": [\"36509738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"N-glycosylation of MERTK at asparagine 294 and 454 stabilizes the receptor and promotes oncogenic transformation in hepatocellular carcinoma; non-glycosylated MERTK localizes to the nucleus and is required for HCC cell survival under stress; MERTK ablation increases ROS production and promotes switching from glycolytic to oxidative phosphorylation metabolism.\",\n      \"method\": \"N-glycosylation site mutagenesis, subcellular fractionation, metabolic assays (glycolysis/OXPHOS), ROS measurement, tumor growth assays\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-directed mutagenesis of glycosylation sites with multiple functional readouts including subcellular localization, single lab\",\n      \"pmids\": [\"35728303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MerTK activation by Gas6 induces MERTK phosphorylation and downstream Akt activation in macrophages; MerTK-activated macrophages produce a secretome (including VEGF-A) that promotes HSC migration, proliferation, viability, and profibrogenic factor expression through STAT3 and p38 signaling in hepatic stellate cells; these effects are specifically blocked by MerTK pharmacologic inhibition (UNC569) or knockdown.\",\n      \"method\": \"Gas6 stimulation, UNC569 pharmacological inhibition, siRNA knockdown, conditioned medium transfer to HSCs, Boyden chamber migration, BrdU proliferation, STAT3/p38/ERK1/2 Western blotting\",\n      \"journal\": \"JHEP reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic inhibition with conditioned medium mechanistic approach, single lab\",\n      \"pmids\": [\"35252828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Arid3a negatively regulates Mertk transcription in macrophages by directly binding to the Mertk promoter (confirmed by ChIP-seq and luciferase reporter assay); Arid3a-deficient macrophages show enhanced Mertk-mediated efferocytosis of apoptotic cholangiocytes; myeloid-specific Arid3a deletion alleviates cholestatic liver injury in a Mertk-dependent manner.\",\n      \"method\": \"ChIP-seq, luciferase reporter assay, myeloid-specific Arid3a knockout mice, three cholestatic mouse models, Mertk inhibitor (UNC2025) in vivo and in vitro, flow cytometry\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct promoter binding by ChIP-seq plus luciferase reporter, genetic rescue with Mertk inhibitor in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"37659731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MERTK expressed in endothelial cells maintains endothelial barrier function by regulating adherens junction structure, junction protein levels, and basal Rac1 activity; siRNA knockdown of MERTK in human pulmonary microvascular endothelial cells enhances neutrophil transendothelial migration and increases dextran permeability. However, endothelial cell-specific Mertk deletion in vivo (iEC Mertk-/- mice) did not replicate aggravated inflammation in P. aeruginosa pneumonia.\",\n      \"method\": \"siRNA knockdown in primary human endothelial cells, dextran permeability assay, Rac1 activity assay, adherens junction analysis, inducible endothelial-specific Mertk-/- mice, in vivo P. aeruginosa pneumonia model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro mechanism identified (Rac1/adherens junctions) but in vivo endothelial-specific KO did not confirm, partial mechanistic support\",\n      \"pmids\": [\"31805065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Stress hormones increase MERTK expression in astrocytes through glucocorticoid receptor (GR) activation, driving astrocyte-mediated excitatory post-synapse phagocytosis; early social deprivation activates the GR-MERTK pathway specifically in astrocytes; ablation of GR or MERTK in astrocytes prevents loss of excitatory synapses, abnormal neuronal network activity, and behavioral abnormalities.\",\n      \"method\": \"Astrocyte-specific conditional knockout of GR and Mertk, in vitro stress hormone treatment, human brain organoid experiments, synapse quantification, EEG, behavioral assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional knockouts with defined GR-MERTK transcriptional pathway, multiple orthogonal readouts including behavioral outcomes\",\n      \"pmids\": [\"37527657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"KLF4 transcription factor mediates training-induced MERTK upregulation in alveolar macrophages; KLF4-driven MERTK expression expands a MERTKhiMarcohiCD163+F4/80low tissue-resident AM subset with enhanced efferocytosis capacity; adoptive transfer of trained AMs restricts inflammatory lung injury.\",\n      \"method\": \"Transcriptomic analysis, KLF4 ChIP (implied by KLF4 overexpression/knockdown), single-cell mass cytometry, lineage tracing, adoptive transfer experiments\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcription factor identified with functional efferocytosis and adoptive transfer validation, single lab\",\n      \"pmids\": [\"37615937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"EphA4 receptor tyrosine kinase suppresses MERTK expression and efferocytosis in monocytes/macrophages via inhibition of the ERK/Stat6 signaling pathway; loss of EphA4 increases mRNA expression of Mertk and Gas6, enhances efferocytosis, and improves functional outcome after brain injury; selective ERK and Stat6 inhibitors attenuate this effect.\",\n      \"method\": \"GFP bone marrow chimeric EphA4 knockout mice, single-cell RNAseq, in vitro efferocytosis assay, ERK/Stat6 inhibitors, immunolocalization of p-ERK/p-Stat6 with MERTK\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with pharmacological pathway validation, single lab\",\n      \"pmids\": [\"37941008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MerTK renders hepatocellular carcinoma resistant to anti-PD-1/PD-L1 therapy by limiting ferroptosis via upregulation of SLC7A11 through the ERK/SP1 pathway, and by facilitating MDSC recruitment to the tumor microenvironment; MerTK inhibition (sitravatinib) sensitizes resistant HCC to anti-PD-L1 by promoting ferroptosis and decreasing MDSC infiltration.\",\n      \"method\": \"Syngeneic mouse HCC models, MERTK knockdown/overexpression, SLC7A11 expression analysis, ERK/SP1 pathway analysis, MDSC flow cytometry, sitravatinib pharmacological treatment\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological approach in two syngeneic models with defined ERK/SP1/SLC7A11 pathway, single lab\",\n      \"pmids\": [\"38382467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MERTK is identified as a TGFβ-inducible effector of fibrosis in multiple organs; MERTK induces TGFβ expression and drives TGFβ signaling in a positive feedback loop; MERTK regulates both canonical and noncanonical TGFβ signaling; MERTK increases transcription of fibrosis genes by modulating chromatin accessibility and RNA polymerase II activity; pharmacological MERTK inhibition reduces fibrosis in liver, kidney, and lung mouse models even after fibrosis is established.\",\n      \"method\": \"Human HSC and macrophage in vitro studies, three mouse fibrosis models (liver, kidney, lung), chromatin accessibility assays, RNA polymerase II activity assays, TGFβ signaling analysis, pharmacological MERTK inhibition\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — defined positive feedback loop with chromatin-level mechanism, replicated across three organ fibrosis models with pharmacological validation\",\n      \"pmids\": [\"38569018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MerTK mediates non-inflammatory phagocytosis of alpha-synuclein fibrils by human microglia: pharmacological MerTK inhibition and siRNA knockdown both decrease the rate of alpha-synuclein fibril internalization; alpha-synuclein fibril uptake via MerTK does not induce pro-inflammatory cytokines (IL-6, TNF) and downmodulates IL-1β, consistent with non-inflammatory MerTK-mediated phagocytosis.\",\n      \"method\": \"Human primary and iPSC-derived microglia, pharmacological MerTK inhibition, siRNA knockdown, cytokine secretion assays, fibril internalization quantification\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent inhibitory approaches (pharmacological and siRNA) in human microglia with multiple functional readouts, single lab\",\n      \"pmids\": [\"37671615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ALKAL1, a target gene of the aryl hydrocarbon receptor (AhR), facilitates MerTK phosphorylation in tumor-associated macrophages, resulting in heightened phagocytic activity and subsequent polarization toward an immunosuppressive phenotype; AhR antagonist delivery to tumor-associated macrophages suppresses MerTK expression and improves anti-PD-L1 efficacy.\",\n      \"method\": \"Single-cell RNAseq, adoptive transfer of MerTK+ macrophages, mechanistic ALKAL1/AhR studies, AhR antagonist in mannosylated micelles, MerTK phosphorylation assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic ALKAL1-AhR-MerTK phosphorylation pathway with functional validation including adoptive transfer, single lab\",\n      \"pmids\": [\"39365866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Staphylococcus aureus vesicles (SAVs) activate the TLR2-MyD88-p38 MAPK signaling pathway to promote cleavage/shedding of MerTK from macrophage surfaces, thereby inhibiting efferocytosis; selective p38 MAPK inhibition prevents MerTK shedding, restores efferocytosis, and accelerates wound healing.\",\n      \"method\": \"Purified SAVs, TLR2/MyD88/p38 pathway analysis (Western blot, siRNA), MerTK shedding quantification by flow cytometry and RNA-seq, p38 MAPK inhibitor treatment, in vivo wound healing model\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined TLR2-MyD88-p38-MerTK cleavage axis with siRNA and pharmacological validation in vitro and in vivo, single lab\",\n      \"pmids\": [\"39780180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"UNC1062 is a pyrazolopyrimidine sulfonamide MerTK inhibitor with IC50 = 1.1 nM; in cancer cells it inhibits MerTK phosphorylation and colony formation in soft agar, confirming the functional importance of MerTK kinase activity in oncogenic transformation.\",\n      \"method\": \"Kinase biochemical assay, cell-based MerTK phosphorylation assay, soft agar colony formation\",\n      \"journal\": \"European journal of medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with cell-based functional readout, single lab\",\n      \"pmids\": [\"23693152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BMS794833 inhibits MERTK by binding to both the ATP-binding pocket and an allosteric back pocket (rendering MERTK inactive), as shown by X-ray co-crystal structure; it competitively inhibits MERTK autophosphorylation in macrophages and significantly inhibits macrophage efferocytosis in vitro and in vivo.\",\n      \"method\": \"X-ray co-crystal structure of BMS794833-MERTK, homogeneous time-resolved fluorescence kinetic assay, Western blotting for MERTK autophosphorylation, real-time efferocytosis monitoring, in vivo mouse efferocytosis model\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — X-ray crystal structure with kinase assay and functional cellular/in vivo validation, single lab\",\n      \"pmids\": [\"36056187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MerTK promotes macrophage survival following oxidative stress (H2O2): H2O2 triggers Mer phosphorylation in a Gas6-dependent manner; MerTK signaling increases pAkt and pErk1/2 (3-fold and 4.5-fold respectively), decreases PARP and Caspase-3 cleavage, and provides up to 2-fold enhanced survival to macrophages; warfarin or MerFc (blocking Gas6) prevents H2O2-mediated Mer activation.\",\n      \"method\": \"H2O2 treatment, warfarin/MerFc Gas6 inhibition, Mer knockout macrophages, Western blotting for pAkt/pErk/PARP/Caspase-3, cell viability assay\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ligand-dependence established with multiple inhibitors, Mer KO comparison, specific downstream readouts, single lab\",\n      \"pmids\": [\"19386698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MerTK in dendritic cells negatively regulates BAFF production: mertk-/- mice contain elevated splenic DCs with elevated proportion of BAFF-secreting cells; mertk-/- BMDCs also have elevated BAFF-secreting cells at rest and after LPS or apoptotic cell stimulation; however, despite more BAFF-secreting cells, mertk-/- BMDCs are not superior at promoting B cell survival.\",\n      \"method\": \"mertk-/- mice, flow cytometry, BAFF decoy receptor blocking, DC-B cell co-culture survival assay\",\n      \"journal\": \"Autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with functional cytokine and cell survival readouts; negative finding on B cell survival is explicitly noted, single lab\",\n      \"pmids\": [\"19301199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Pentoxifylline (PTX) alleviates ischemic white matter injury through PPAR-γ nuclear translocation, which upregulates Mertk expression in microglia; microglia-specific Mertk knockout blocks the therapeutic effects of PTX in BCAS model; PTX-upregulated Mertk enhances microglial phagocytosis of myelin debris.\",\n      \"method\": \"BCAS mouse model (bilateral common carotid artery stenosis), microglia-specific Mertk knockout mice, Mertk inhibitor, PPAR-γ inhibitor, immunofluorescence, Western blotting, flow cytometry\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — microglia-specific KO with PPAR-γ inhibitor confirming regulatory pathway, single lab\",\n      \"pmids\": [\"35642056\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MERTK is a receptor tyrosine kinase that functions as the central mediator of efferocytosis (apoptotic cell clearance) across multiple cell types including macrophages, microglia, astrocytes, retinal pigment epithelium, and platelets; upon binding its vitamin K-dependent bridging ligands Gas6 and Protein S (which engage phosphatidylserine on apoptotic cells), MERTK undergoes autophosphorylation and activates downstream signaling cascades including PI3K/AKT, MAPK/ERK, PLCγ2, JAK/STAT, RHOA-ROCK, and SOCS1/3, driving phagocytic engulfment, cell survival, and anti-inflammatory responses; MERTK surface availability is dynamically regulated by proteolytic shedding (via ADAM17 and ADAM9) that generates a decoy soluble receptor, while its transcription is controlled by KLF4, PPAR-γ, glucocorticoid receptor, and Arid3a; in the CNS, microglial MERTK eliminates phosphatidylserine-displaying inhibitory synapses and myelin debris, and in osteoblasts MERTK-PROS1 signaling negatively regulates bone formation via the VAV2-RHOA-ROCK axis, illustrating tissue-specific functional diversity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MERTK is a transmembrane receptor tyrosine kinase of the Axl family that serves as a central engulfment receptor coupling recognition of phosphatidylserine on apoptotic cells, debris, and synapses to phagocytic clearance and anti-inflammatory signaling across macrophages, microglia, astrocytes, dendritic cells, retinal pigment epithelium, and platelets [#1, #0, #12]. The receptor carries extracellular immunoglobulin and fibronectin type III domains and an intracellular kinase, and an alternatively spliced soluble form was recognized at cloning [#1]. Engulfment is driven by bridging ligands — Gas6, Protein S/PROS1, and the Tubby/Tulp1 proteins — that link MERTK to phosphatidylserine on apoptotic targets, inducing receptor autophosphorylation [#5, #12]. Ligand binding distinguishes two steps: kinase-independent tethering and kinase-dependent engulfment, the latter shown to be obligatory for efferocytosis in kinase-dead mice and human iPSC-derived macrophages [#12, #27]. Downstream, MERTK recruits PLCγ2 during apoptotic-cell engulfment [#2] and activates PI3K/AKT, MAPK/ERK, JAK/STAT, and STAT6 cascades that promote phagocytosis, cell survival under oxidative stress, and anti-inflammatory cytokine output including IL-10, TGF-β, and SOCS1/3 induction [#7, #8, #47, #25]. MERTK surface availability is governed by proteolytic shedding that generates a soluble decoy receptor; cleavage-resistant knock-in models establish that limiting shedding enhances efferocytosis and tissue resolution in atherosclerosis and modulates fibrosis, while pathways acting through ADAM17 (microRNA-26a, TLR2-MyD88-p38) tune shedding up or down [#11, #16, #24, #44]. Its transcription is controlled by KLF4, PPAR-γ, the glucocorticoid receptor, and the repressor Arid3a, providing context-specific induction in trained macrophages, microglia, and stress-exposed astrocytes [#38, #49, #37, #35]. In the CNS, MERTK mediates phosphatidylserine-dependent elimination of inhibitory and excitatory synapses, clearance of myelin debris during remyelination, and non-inflammatory uptake of alpha-synuclein fibrils [#28, #37, #29, #42]. In disease contexts MERTK drives tumor survival, invasion, immune evasion via the PD-1/PD-L1 axis, therapy resistance, and a TGF-β-coupled profibrotic program in liver, kidney, and lung, and in osteoblasts PROS1-MERTK signaling represses bone formation through a VAV2-RHOA-ROCK axis [#7, #8, #20, #41, #32]. Loss-of-function mutation of Mertk causes failure of RPE phagocytosis of photoreceptor outer segments and retinal degeneration [#0].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established MERTK's molecular identity as a novel receptor tyrosine kinase, defining the domain architecture and expression pattern that frame all later mechanistic work.\",\n      \"evidence\": \"cDNA expression cloning, sequence and domain analysis, Northern blot expression profiling\",\n      \"pmids\": [\"8086340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No ligand identified at cloning\", \"Functional role of the truncated soluble splice form not tested\", \"Catalytic activity inferred from sequence motif, not assayed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Linked MERTK loss to a defined phagocytic failure in vivo, showing the receptor is essential for RPE clearance of photoreceptor outer segments and causally tied to retinal dystrophy.\",\n      \"evidence\": \"Positional cloning and genomic deletion mapping in the RCS rat retinal dystrophy model\",\n      \"pmids\": [\"10699188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the bridging ligands engaging MERTK in RPE\", \"Downstream signaling of phagocytosis unresolved\", \"Generalizability beyond RPE not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Connected receptor activation to an immediate phagocytic effector by showing PLCγ2 recruitment and activation downstream of MERTK during apoptotic-cell engulfment.\",\n      \"evidence\": \"Reciprocal Co-IP and PI-PLC inhibition in peritoneal macrophages and J774 cells\",\n      \"pmids\": [\"14704368\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single lab, two cell systems\", \"Direct vs adaptor-mediated MERTK-PLCγ2 interaction not resolved\", \"Link to cytoskeletal engulfment machinery not mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Extended MERTK function beyond clearance to platelet biology, identifying it as the dominant platelet Gas6 receptor required for aggregation and thrombosis.\",\n      \"evidence\": \"Mer knockout mice, in vitro aggregation assays, in vivo thrombosis models\",\n      \"pmids\": [\"15130911\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Platelet-intrinsic signaling pathway not delineated\", \"Whether MERTK acts cell-autonomously in platelets not formally separated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined MERTK as a pro-survival and immune-regulatory receptor, showing Gas6-dependent activation protects macrophages from oxidative stress and that DC MERTK restrains BAFF production.\",\n      \"evidence\": \"H2O2 treatment with Gas6 blockade and Mer-KO macrophages; mertk-/- mice with BAFF and B-cell co-culture readouts\",\n      \"pmids\": [\"19386698\", \"19301199\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"BAFF effect did not translate to enhanced B-cell survival\", \"AKT/ERK survival readouts single lab\", \"Mechanism linking MERTK to BAFF transcription unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Broadened the MERTK ligand repertoire beyond Gas6/Protein S by identifying Tubby and Tulp1 as bridging molecules and mapping their minimal MERTK-binding motifs.\",\n      \"evidence\": \"Co-IP, receptor phosphorylation, soluble-ectodomain blocking, and domain mutagenesis\",\n      \"pmids\": [\"20978472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological tissue context of Tubby/Tulp1-MERTK engagement not established in vivo\", \"Receptor selectivity among TAM members partially overlapping\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified MERTK as a driver of tumor invasion and apoptosis resistance, linking it to actomyosin contractility via myosin light chain 2 phosphorylation in glioblastoma.\",\n      \"evidence\": \"shRNA knockdown, inactive-mutant overexpression, invasion assays, MLC2 phospho-blotting\",\n      \"pmids\": [\"22469987\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct kinase substrates upstream of MLC2 not mapped\", \"Ligand dependence in tumor setting not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established MERTK as an oncogenic signaling hub in melanoma and AML, mapping Gas6-driven activation to MAPK/ERK, PI3K/AKT, and JAK/STAT prosurvival pathways, and validated kinase activity pharmacologically.\",\n      \"evidence\": \"Gas6 stimulation with downstream phospho-blotting, shRNA knockdown, xenografts, and the UNC1062 kinase inhibitor\",\n      \"pmids\": [\"23585477\", \"23474756\", \"23617806\", \"23693152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each downstream pathway to tumor phenotype not dissected\", \"CDC42 and AKT dependencies from a single melanoma study\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Distinguished MERTK's phagocytic and shedding functions, showing it confers efferocytosis and PD-L1/chemoresistance in epithelial/breast cells and that proteolytic shedding produces a decoy soluble receptor limiting RPE phagocytosis.\",\n      \"evidence\": \"Gain/loss-of-function efferocytosis assays; conditioned-media shedding analysis with metalloprotease inhibitors in RPE\",\n      \"pmids\": [\"25074939\", \"25538233\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Protease identity not definitively assigned in these studies\", \"PD-L1 induction mechanism downstream of MERTK unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mechanistically dissected efferocytosis into kinase-independent tethering and kinase-dependent engulfment, and revealed MERTK as a PROS1 decoy regulating T-cell activation; also defined Tyro3 as a genetic modifier of MERTK retinal function.\",\n      \"evidence\": \"Kinase-dead Mer mutants and tethering/engulfment assays; Mer-Fc PROS1 competition in DC-T cocultures; Mertk/Tyro3 double-knockout mice with eQTL mapping\",\n      \"pmids\": [\"25695599\", \"25624460\", \"26656104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of kinase-independent tethering not resolved\", \"Functional redundancy between TAM receptors context-dependent\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided structural and in vivo proof that MERTK cleavage state governs tissue resolution, and delivered co-crystal structures defining the druggable ATP pocket exploited for selective inhibitors.\",\n      \"evidence\": \"Cleavage-resistant MerTK knock-in mice in atherosclerosis with human plaque correlation; X-ray co-crystal structures with macrocyclic inhibitors and SAR; evolutionary mutagenesis of signal peptide/TM domain\",\n      \"pmids\": [\"28067670\", \"28032464\", \"27994735\", \"28369510\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of the ligand-bound ectodomain\", \"Conformational changes on autophosphorylation not captured\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Positioned MERTK as a node in tumor immune evasion and therapy resistance, controlling the PD-1/PD-L1 axis in the leukemia microenvironment and mediating resistance to AXL-targeted agents.\",\n      \"evidence\": \"Mertk-/- mice and MRX-2843 inhibitor with immune profiling; AXL-inhibitor models with MERTK overexpression/knockdown and dual inhibition in vivo\",\n      \"pmids\": [\"30385715\", \"30093568\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether checkpoint regulation is efferocytosis-dependent not fully separated\", \"AXL/MERTK cross-resistance mechanism single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed MERTK's profibrotic and immunoregulatory signaling in tissue contexts, driving NASH fibrosis via ERK-TGFβ1, acting as a CD8 T-cell costimulatory receptor, and being stabilized by extracellular-vesicle microRNA-26a that suppresses ADAM17.\",\n      \"evidence\": \"Mertk KO and cleavage-resistant knock-in NASH models; CD8 T-cell PROS1/MERTK functional assays; miR-26a/Adam17 EV studies in MerTK-deficient animals\",\n      \"pmids\": [\"31839486\", \"31266785\", \"31434491\", \"31805065\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endothelial-specific role not confirmed in vivo\", \"Cell-type origin of profibrotic MERTK signal partially overlapping\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined how MERTK enforces anti-inflammatory tone during viral infection and how its transcription is metabolically and developmentally controlled, linking apoptotic-cell sensing to SOCS1/3-mediated innate anergy and polyamine/ODC-dependent expression.\",\n      \"evidence\": \"Mertk-/- mice in VSV infection with SOCS1/3 and cytokine readouts; ODC-deficient macrophages with histone-methylation and putrescine rescue\",\n      \"pmids\": [\"32187540\", \"33406854\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcription factors at the Mertk locus in these contexts not fully identified\", \"Single lab per finding\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Cemented MERTK as the microglial/astrocytic phagocytic receptor for phosphatidylserine-displaying synapses and myelin debris in the CNS, and confirmed its kinase activity is required for efferocytosis in vivo and in human macrophages.\",\n      \"evidence\": \"Conditional microglial Mertk KO with synapse and seizure readouts; cuprizone demyelination scRNA-seq; kinase-dead Mertk mice plus human iPSC macrophages; PPAR-γ-PTX microglial KO model\",\n      \"pmids\": [\"34013588\", \"33691116\", \"34035216\", \"35642056\", \"34415994\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals selecting which synapses expose phosphatidylserine partly upstream of MERTK\", \"IFNγ counter-regulation mechanism incompletely mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Expanded MERTK regulation and tissue function: defined Arid3a as a direct transcriptional repressor, the GR and KLF4 as inducers, a PROS1-VAV2-RHOA-ROCK axis repressing bone formation, an allosteric inhibitor-binding pocket, and N-glycosylation-controlled stability/localization.\",\n      \"evidence\": \"ChIP-seq and luciferase for Arid3a; cell-type-specific GR/KLF4/osteoblast Mertk conditional KOs; BMS794833 co-crystal structure; glycosylation-site mutagenesis; Tim-4 FnIII-domain Co-IP\",\n      \"pmids\": [\"37659731\", \"37527657\", \"37615937\", \"36509738\", \"36056187\", \"35728303\", \"32640697\", \"35252828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Coordination among multiple transcriptional regulators not integrated\", \"Nuclear MERTK function mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Generalized MERTK as a TGFβ-coupled profibrotic effector acting at the chromatin level across organs and as a multifaceted driver of immunotherapy resistance via ferroptosis suppression, MDSC recruitment, and macrophage polarization.\",\n      \"evidence\": \"Three-organ fibrosis models with chromatin-accessibility and Pol II assays; HCC syngeneic models with SLC7A11/ERK-SP1 and MDSC analysis; ALKAL1-AhR-MerTK phosphorylation studies; alpha-synuclein fibril uptake in human microglia; S. aureus vesicle TLR2-p38 shedding axis\",\n      \"pmids\": [\"38569018\", \"38382467\", \"39365866\", \"37671615\", \"39780180\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How a surface RTK modulates chromatin accessibility mechanistically not resolved\", \"Several pathways from single labs awaiting independent confirmation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How MERTK ligand engagement is structurally transduced into the divergent tissue-specific outputs — phagocytic engulfment, prosurvival signaling, profibrotic chromatin remodeling, and bone/synapse suppression — and how the multiple transcriptional and shedding regulators are integrated in a given cell, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No ligand-bound ectodomain structure linking binding to activation\", \"Mechanism by which a membrane RTK alters chromatin accessibility unknown\", \"Integration of KLF4/PPARγ/GR/Arid3a transcriptional inputs uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 12, 27, 2]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [17, 18, 46]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [0, 12, 5, 28]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [7, 8, 47]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 12, 11]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [11, 1, 13]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 20, 25, 31]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 8, 47, 2]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 12, 27, 28]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [16, 23, 41, 40]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GAS6\", \"PROS1\", \"PLCG2\", \"TYRO3\", \"AXL\", \"TIMD4\", \"TULP1\", \"ALKAL1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":10,"faith_total":10,"faith_pct":100.0}}